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…….You’ve got to find what you love. And that is as true for 
your work as it is for your lovers. Your work is going to fill a 
large part of your life, and the only way to be truly satisfied is 
to do what you believe is great work. And the only way to do 
great work is to love what you do. If you haven't found it yet, 
keep looking. Don't settle. As with all matters of the heart, 
you'll know when you find it. And, like any great relationship, 
it just gets better and better as the years roll on. So keep 
looking until you find it. Don't settle. 
 
                                                       Stay Hungry. Stay Foolish. 
                  
                                                        Steve Jobs, June 12, 2005. 
 
 
 
 
To Myself, my Strength, my Courage, my Determination, and 
especially to my PASSION….  
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                                                                                  Chapter 1 
 
                                             Introduction 
 
ABSTRACT. The most widely accepted definition of a biosensors is: “a self-contained 
analytical device that incorporates a biologically active material in intimate contact with an 
appropriate transduction element for the purpose of detecting (reversibly and selectively) the 
concentration or activity of chemical species in any type of sample [1].Clark and Lyons 
developed the first biosensor, an enzyme-based glucose sensor [1]. Since then, hundreds of 
biosensors have been developed in many research laboratories around the world. The 
objective of this chapter is to underline the principles of biosensors science and their potential 
applications in the food, agricultural industries and biomedical fields.  
1.1. Biosensors 
Molecular recognition events are some of the most significant features of biological and 
chemical systems. The biomolecular recognition is the ability of a biomolecule to interact 
selectively with another molecule even in the presence of structurally similar antagonist 
molecules [2]. This basic principle is not only important from a scientific point of view but 
also to open an important window in the field of biotechnological applications. The 
recognition process itself is governed by non-covalent interactions as salt bridges, hydrogen 
bonds, van der Waals forces, hydrophobic interactions, and entropic effects [3]. Molecular 
recognition is fundamental for biosensing technique. Before the various types of biosensor 
technologies and application are discussed, it is first important to understand and define 
‘biosensor’. A biosensor, according to IUPAC recommendations 1999, is an independently 
integrated receptor transducer device, which is capable of providing selective quantitative or 
semi-quantitative analytical information using a biological recognition element [4]. 
Essentially it is an analytical device made by a biological recognition element to detect 
specific analyte integrated with a transducer to convert a biological signal into an electrical 
signal [5]. The aim of a biosensor is to provide rapid, real-time, accurate and reliable 
information about the studied analyte [6]. In recent years biosensors acquired a significant 
analytical role in medicine, agriculture, food safety, homeland security, bio-processing, 
environmental and industrial monitoring [7]. A biosensor consists of three main elements, a 
 11 
 
bioreceptor (antibody, proteins, peptide, nucleic acids, that are able to detect the specific 
target analyte,), a transducer (device that converts the biomedical signal between analyte and 
bioreceptor in an electrical or chemical signal), and a signal processing system ( it is 
responsible of signal amplification and data processing), [8]. Figure 1 shows a schematic 
diagram of the typical components in a biosensor.  
             
   Figure 1.1: Schematic diagram of the typical components in a biosensor.  
 
The first kind of biosensor device was developed in 1967 by Updike and Hicks and it 
consisted of a molecular recognition element and a transducer. This biosensor was able to 
detect glucose concentration in the blood basing its functionality on hydrogen peroxide 
production by glucose oxidase using dissolved oxygen without the aid of mediators and 
cofactors (Figure 2A). Based on this technology, Yellow Spring Instrument Company, 
launched the first commercial glucose biosensor in market in 1975 for the direct blood 
glucose measurement. This kind of device was quickly replaced by a second generation of 
glucose biosensor that utilized redox mediators to transfer electrons from the enzyme to the 
working electrode surface (Figure 2B). The use of redox mediators and cofactors eliminated 
the need of oxygen for electron transfer at the electrode surface overcoming the drawback of 
limited oxygen pressure observed in the first generation biosensor. In the recent period a third 
and fourth glucose biosensor generation were developed. The former is based on a direct 
electron transfer between active centre of enzyme and a carbon nanotube electrode surface 
(Figure 2C), while the latter is about the use of a non-enzymatic electrode surface such as 
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active metal micro and nano-particles that mediate oxidation of the adsorbed species (Figure 
2D).   
      
Figure 1.2: Schematic representation of glucose detection biosensors. A) First generation of 
glucose device made only by analyte and transducer component. Its functionality is based on 
hydrogen peroxide production by glucose oxidase using dissolved oxygen without the aid of 
mediators and cofactors. B) The second generation of glucose detection biosensor uses the 
help of redox mediators to transfer electrons from the enzyme to the working electrode 
surface, reducing oxygen high pressure observed in the first generation. C) and D) Third and 
fourth biosensors generation, respectively, based on use of carbon nanotube and metal active 
micro and nano-particles to a more accurate glucose detection in the blood. 
Over the years several techniques have progressively been associated to provide a more 
accurate detection of target analytes, including different kinds of transducers elements and 
several biorecognition elements. 
1.1.2 Classification of biosensors 
Biosensors can be classified on the basis of biological signaling mechanism used or by the 
type of signal transduction employed. Figure 3 shows the different categories of biosensor. 
 
A B
C
D
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Figure 1.3: Diagram of different categories of biosensors based on bioreceptor and/or 
transducer element used. 
The bioreceptor or biological recognition element is the most important and significant 
feature of a biosensor. The bioreceptor is the heart of the recognition system of a sensor 
towards the target analyte. Essentially it is crucial for a bioreceptor to be selective and 
sensitive towards the specific target in order to prevent the interference by other substance 
from sample matrix [5]. Generally biosensors can be classified by the type of biological 
signaling mechanism they utilize. The biological signaling used by biosensors can be divided 
into three major mechanisms (Figure 3): 
Enzyme based sensor: Enzyme based biosensor is the first biosensor introduced by Clark 
and Lyons in 1962 as an amperometric enzyme electrode for glucose detection in the blood 
[9]. Since the first biodevice, enzyme based biosensor has a massive growth in usage for 
various biotechnological applications still present. Enzymes are very efficient biocatalysts, 
which have the ability to recognize their substrates and to catalyze their transformation in a 
specific way. These unique properties make the enzymes powerful tools to develop analytical 
devices [10]. Enzyme-based biosensors associate a biocatalyst-containing sensing layer with 
a transducer. These devices working primarily on catalytic action and binding capability in 
order to have a specific analyte detection [8]. The enzyme based biosensors were made of 
enzyme as bioreceptor which is specific to detect studied analyte from a sample matrix. The 
lock and key and induced fit hypothesis can apply to explain the mechanism of enzyme 
action which is highly specific for this type of biosensor. This specific catalytic reaction of 
the enzyme provides a biosensor with the ability to detect much lower limits than with 
normal binding techniques. This high specificity of enzyme–substrate interactions and the 
usually high turnover rates of biocatalysts are the origin of sensitive and specific enzyme-
based biosensor devices [10]. Ideally enzyme catalytic action can be influence by several 
factors such as the concentration of the substrate, temperature, presence of competitive and 
non-competitive inhibitor and pH [11]. Essentially the Michaelis-Menten equation can be 
used to further explain the detection limit of enzyme based biosensor [12]. Glucose oxidase 
Biosensor
TransducerBioreceptor
Enzyme Antibody
DNA e/or
Biomimetic
Electrochemical Optical
Piezoelectric
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13 (GOD) and horseradish peroxidase (HRP) are the most widely used enzyme based 
biosensor that has been reported in literature, even if some recent studies have shown that 
enzyme based biosensor can be used to detect cholesterol, food safety and environmental 
monitoring, heavy metals and also pesticides [13-17]. Moreover, a recent studies reported the 
used of an enzyme biosensor with nucleic acid incorporated for DNA detection [18,19]. 
Immunosensors: An antibodies based biosensor was applied for the first time in the 1950s, 
opening the doors of immuno-diagnosis [20]. Immunosensors are devices composed by an 
antigen/antibody as bioreceptor box. An antibody is a ‘Y’ shaped immunoglobin (Ig) made 
up of two heavy chains (H) and two light chains (L). However some of human antibodies 
form dimeric or pentameric structure by utilizing disulphide bonds and an extra protein called 
the joining or J- chain [21, 22]. Each of the chains has a constant and variable part and this 
latter one is specific to the antigen that is bound in an highly specific and selective way [23, 
20]. The specificity of an antibody towards the binding side of its antigen is a function of its 
amio acids [24]. Immunosensors play an important role in the improvement of public health 
in areas such as clinical chemistry, food quality and environmental monitoring thanks their 
rapid detection, high sensitivity, and specificity properties. The development of 
immunosensors for bacteria, pathogen and toxins detection opened the doors  in the point of 
care measurement (POC), [25-28]. Some recent studies shown that immunosensor is widely 
explored toward the detection of cancer/tumor. Because of the traditional diagnostics 
methods are poor in sensitivity, selectivity and time consuming, immunosensors seem to be 
promising tools for cancer detection also in its early stages [29]. 
Nucleic acid sensor: The use of nucleic acids sequences for specific diagnostic applications 
has developed since the early 1953 and still growing widely [30]. The highly specific affinity 
binding reaction between two single strand DNA (ssDNA) chains to form double stranded  
DNA (dsDNA) is utilized in nucleic acids based biosensor . This biosensor works primarily 
on recognition of the complementary strand by ssDNA to form stable hydrogen bond 
between two nucleic acids to become dsDNA. For this reason an immobilized ssDNA 
complementary to the target analyte is used as probe in bioreceptor box. Exposure of target to 
the probe results in hybridization of complementary ssDNA producing a biochemical reaction 
that will be amplified and converted in an electrical signal by a transducer. However, 
literature shows that the present of some linker such as thiol or biotin is needed in the effort 
to immobilize the ssDNA onto the sensing surface [31, 32]. An important property of DNA is 
that the nucleic acid ligands can be denatured to reverse binding and the regenerated by 
controlling buffer ion concentration [12]. DNA based biosensor has potential application in 
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clinical diagnostic for virus and disease detection [33-35]. In addition, this kind of biosensor 
possesses a remarkable specificity to provide analytical tools that can measure the presence 
of a single molecule species in a complex mixture as blood or other biological fluids [36]. 
Biomimetic sensor: A biomimetic biosensor is an artificial or synthetic sensor that mimics 
the function of a natural biosensor. These can include aptasensors, where aptamers are the 
biocomponent used [8]. Aptamers were reported for the first time in the early 1990s and they 
were described as artificial nucleic acid ligands. They are synthetic strands of nucleic acid 
that can be designed to recognize amino acids, oligosaccharides, peptides, and proteins. An 
aptamer has few advantages over antibody based biosensor such as high binding efficiency 
and avoiding the use of animal that reduces ethical problems. Aptamer properties such as 
their high specificity, small size, modification and immobilization versatility, regenerability 
or conformational change induced by the target binding have been successfully exploited to 
optimize a variety of bio-sensing formats [37]. Aptamer based biosensor has been widely 
used in various application. Recently great progresses have been made in biomimetics sensor 
and aptasensor for clinical application [38], including clinical diagnostics to detect pathogen, 
virus and infectious disease [39-42].  
Biosensor are normally categorized according to the transduction method they employ 
(Figure 3). The transducer plays an important role in the signal detection process. It can be 
defined as a device that converts a wide range of physical, chemical or biological effects into 
an electrical signal with high sensitivity and minimum disturbance to the measurement [5]. 
There are various numbers of transducer methods developed over the decade; but they can be 
divided in tree big categories: electrochemical, optical and piezoelectric.  These groups can 
be further divided into two general categories; labeled and label free type, which label free 
type biosensors growing further recently [12]. 
Electrochemical sensors: Electrochemical biosensors measure the change that results from 
the interaction between the analyte and the sensing surface of the detecting electrode. The 
electrical changes can be based on: 1) change in the measured voltage between the electrodes 
(potentiometric), 2) change in the measured current at a given applied voltage 
(amperometric), and 3) change in the ability of the sensing material to transport charge 
(conductometric). Due to their sensitivity, simplicity, low cost and fast response time, these 
sensors appear more suited for field monitoring applications such as clinical analysis, on-line 
control processes in industry or environment, and even in vivo studies [43,44].  
Optical biosensors: Optical sensors transduce a biological event using an optical signal such 
as absorbance, fluorescence, chemiluminescence, surface plasmon resonance or changes in 
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light reflectivity [45]. Although are advantageous for screening a large number of samples 
simultaneously, it is difficult to miniaturize them for insertion into the bloodstream as most 
optical methods still require sophisticated instruments [44].  
Piezoelectric biosensors: Piezoelectric biosensors operate applying an oscillating voltage at 
a resonance frequency of the piezoelectric crystal and measuring the change in this frequency 
when the analyte interacts with the crystal surface. Acoustic wave devices, including Surface 
Acoustic Wave (SAW) and Bulk Acoustic Wave (BAW) are the most common sensors, 
which bend when a voltage is applied to the crystal. Similarly to optical detection, 
piezoelectric detection requires large sophisticated instruments to monitor the signal [44].  
Piezoelectric biosensors technologies are applied in a wide range of fields for various 
purposes as environmental, food, clinical and national security uses [46]. Furthermore, 
pharmaceutical industry requires this kind of biosensors to accelerate the processes of drug 
discovery and screening. Additionally, public safety has fostered developments in the 
environmental and food/agricultural industry promoting devices for the detection of 
pathogens and pollutants in foodstuffs [47]. 
 
1.2 Peptide based biosensors 
Peptides have been used as components in biological analysis and fabrication of novel 
biosensors for a number of reasons, including ease of large-scale synthesis, handling, and 
storage, as well as ready access to multiply modified analogues containing an array of 
unnatural substituents, highly selectivity for enzymes substrates and low production costs. 
Bio-conjugation strategies can provide an efficient way to convert interaction information 
between peptides and analytes into a measurable signal, which can be used for fabrication of 
novel peptide-based biosensors. Many sensitive fluorophores can respond rapidly to 
environmental changing their spectral characteristics, hence environmentally-sensitive 
fluorophores have been widely used as signal markers to conjugate peptides developing the 
peptide-based molecular sensors. Additionally, nanoparticles, fluorescent polymers, 
grapheme and near infrared dyes are also used as peptide-conjugated signal markers. Peptides 
have been utilized as bio-recognition elements to bind various analytes including, proteins, 
nucleic acid, bacteria, metal ions, enzymes and antibodies in biosensors. The peptides possess 
the necessary properties as recognition flexibility to adapt sterically to any target, rigidity in 
secondary structure to converse the binding aptitude and the propensity to form different 
kinds of non-covalent bonds with potential targets. The recent progresses on microarray 
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techniques using peptides have facilitated the commercial application of chip-based peptide 
biosensors in clinical diagnosis. 
1.2.1 Peptides as recognition elements  
Miniaturized bio-macromolecules offer an alternative strategy to molecular recognition 
elements with selectivity and affinity properties comparable to their natural compound [48]. 
In this context, designed short peptides (up to 20 amino acids) are emerging as excellent 
opportunity for recognition elements development in biosensor field. Short peptides represent 
a clear option for the design of synthetic receptors for a series of reasons: 1) we can obtained 
a very high number of different peptides by the combination of the 21 natural amino acids; 2) 
the availability of both molecular biology and chemical techniques for the fast screening of 
peptide libraries is less time-consuming; 3) the automated synthesis and purification 
technologies are much easier than the technologies used for monoclonal antibody 
preparation; 4) the ease of modifications in a site-specific manner allows for fluorophore 
coupling and immobilization on solid support; 6) the relatively easy modeling permits more 
accurate computational studies. 
A growing number of peptide-based biosensors systems for different target analytes includes 
whole cells, proteins, small organic molecule and ions have been reported recently in 
literature [2]. 
1.2.2 Selection and synthesis strategies for peptide-based sensors 
In the recent years, peptide-based sensors have been developed according to different 
strategies.  
Synthetic design peptides have been designed on the basis of known interactions between 
single or few amino acids and targets, with attention being paid to the presence of peptide 
motifs known to allow intermolecular self-organization of the peptides over the sensor 
surface. Sensitive sensors have been obtained in this way for ions, small molecules and 
proteins (Figure 4). 
Peptides design using computational methods becomes a new and promising way for the 
rational design of peptide agents targeting specific protein-protein interactions (PPIs). The 
design is commonly based on bioinformatics methods or molecular modeling techniques, 
indirectly exploiting structure-activity relationship at the level of peptide sequence or directly 
deriving lead entities from protein complex architecture [49]. 
Short peptides from random phage display have been selected in a random way from 
large, unfocussed, and often preexisting and commercially available libraries with no design 
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element. Such peptides often perform better that antibodies, but they are difficult to select 
when the target is a small molecule because often it has no reactive groups for solid support 
immobilization. 
Peptide receptors for ligand sensing are artificial, miniaturized receptors obtained from 
reduction of the known sequence of a natural receptor down to a synthesizable and yet stable 
one. 
Finally, peptide ligands for receptor sensing are short peptides that have been used as 
active elements for the detection of their own natural receptors. The identification of these 
natural peptide ligands for cell-surface elements, transmembrane proteins, antibodies, and 
enzymes provides a good challenge for biosensor development in bacteria and virus detection 
field. [2]. 
 
                                     
 
Figure 1.4: Ethanol biosensors based on conducting polymers with peptide and ferrocene on 
the side chain [50]. 
1.2.3. Peptide-based fluorescent biosensors 
The development of peptide-based sensors over the last two decades has had a considerable 
success in biotechnology field.  
Fluorescent techniques, due to their high sensitivity, selectivity, fast response time, flexibility 
and experimental simplicity are the key of this approach. FRET (Fluorescence Resonance 
Energy Transfer) effects or environment-sensitive fluorophore provide reliable design 
strategies that can be safely implemented to study virtually any biological interaction with 
minimal efforts [51]. 
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Environment-sensitive fluorophores (Figure 5) are molecules that display emission 
responsive properties to the chemical surrounding [51]. Physiochemical changes include pH, 
viscosity, biological analytes and solvent polarity. By conjugating these probes to a molecule 
(i.e. protein), it is possible to obtain valuable information regarding the state of a protein with 
high spatial and temporal resolution [52].  
                               
 
Figure 1.5: Comparison of some environment-sensitive fluorophores and their solvachomatic 
properties [43]. Abbreviations: 4-DMNA: 4-(N,Ndimethylamino) naphthalimide alanine, 6-
DMNA: 6-(N,N-dimethylamino)-2,3-naphtalimide alanine, DANA/Aladan: 6-(2-
dimethylamino)-naphthoyl alanine, 4-DAPA: 4-(N,N-dimethylamino)-phalimido alanine, 4-
DMAP: 4-(N,N-dimethylamino) phthalimide, DnsA: Dansyl alanine, TAMRA: 5-(and-
6)carboxytetramethyl rhodamine, 6-DMN: 6-dimethylamino-1,8-naphthalimide, 4-DMN: 4-
dimethylamino-1,8-naphthalimide, NbdA: 7-nitrobenzo-2-oxa-1,3-diazole. 
 
Two main strategies for covalent incorporation of a fluorophore in the peptide can be 
distinguished. The first one involves post-synthetic coupling at the N-terminal or at the side 
chains of cysteines or lysines. The second one uses unnatural fluorescent amino acids for 
peptide synthesis [53]. However the insertion of the fluorophore is restricted topologically to 
sites in the protein that preserve function and activity while permitting the dye to make 
necessary contacts that result in measurable fluorescence changes. This consideration 
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necessitates the use of methods that offer precise control over dye placement within peptide, 
with minimal perturbation [52]. 
The Figure 1.6 illustrates the general principle of a fluorescent peptide biosensor, while Table 
1 summarizes environmentally sensitive peptide biosensors. 
Fluorescent sensor peptides have proven useful in a number of applications, ranging from 
analyte detection to elucidation PPIs. It is expected that their general applicability with 
respect to analyte quantification will be expanded by combining combinatorial methods for 
peptide design with further improvements of fluorophores and fluorescent amino acids in 
terms of sensitivity to environmental changes [53]. 
 
 
 
Figure 1.6: Schematic representation of a fluorescent peptide biosensor. A) Peptide probe 
with environment-sensitive fluorophores assignal markers to respond to the target protein; 
(B)excimer-pair peptide sensor,the peptide binds to the target protein,changing the spectral  
property of the fluorophores;(C)FRET/probe–quencher pair  peptidesensor,where the distance 
between the donor–acceptor/probe–quencher was changed by binding of the peptide to the 
protein. 
                 
 
A 
B 
C 
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                   Table 1: Selected environmentally sensitive peptide biosensors [44]. 
 
ANALYTE RECEPTORS FLUOROPHORE 
DNaK chaperone 
Targeting sequence of 
precursor of 
aminotransferase 
Acrylodan 
Cholecystokinin 
(CCK) receptor 
Peptides agonist of the CCK 
receptor 
Alexa 488 
α-amilase 
Library of designed loop 
peptides 
Fluorescein 
Calmodulin 
Library of designed α-helical 
peptides 
TAMRA 
Double-stranded DNA 
Polypeptide derived from the 
Hin recombinase of 
Salmonella typhimurium 
Oxazole yellow 
Opioid-receptor Opioid antagonist DANA (Aladan) 
Class II MHC proteins HLA-DR-binding peptides 
4-DAPA and 6-
DMNA 
 
1.3 Conclusions and outlook 
The past decade has seen great advancements in the field of biosensor along many fronts. 
This dynamic tool has been applied in many area of life science research, health care, 
environmental, food and military application [6]. Biosensor technology seems to be a 
promising candidate for lower detection limit with rapid analysis time at relatively low cost. 
Technological advances have brought up use of materials as supports to construct biochip 
which integrated microfluidic system, probe, sampler, detector, amplifier and logic circuitry. 
This biochip could be a promising candidate for label free, reagentless, real time monitoring, 
miniaturization and low cost application. For medical application, this cost advantage will 
allow the development of extremely low cost, disposable biochips that can be used for in-
home medical diagnostics of diseases without the need of sending samples to a laboratory for 
analysis which time consuming [6]. 
The main aim of the thesis is the development of different miniaturized biosensors and 
microdevices based on peptides for food industry and healthcare.  
 
 
Molecular recognition events are some of the most significant features of biological and 
chemical systems. The biomolecular recognition is the ability of a biomolecule to interact 
selectively with another molecule even in the presence of structurally similar antagonist 
molecules  [1]. Molecular recognition is fundamental for biosensing technique. A biosensor, 
                       Aim and Outline of the Thesis 
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according to IUPAC recommendations 1999, is an independently integrated receptor 
transducer device, which is capable of providing selective quantitative or semi-quantitative 
analytical information using a biological recognition element [2]. A biosensor consists of 
three main elements, a bioreceptor (antibody, proteins, peptide, nucleic acids, that are able to 
detect the specific target analyte,), a transducer (device that converts the biomedical signal 
between analyte and bioreceptor in an electrical or chemical signal), and a signal processing 
system (it is responsible of signal amplification and data processing), [8]. The bioreceptor or 
biological recognition element is the most important and significant feature of a biosensor. 
The bioreceptor is the heart of the recognition system of a sensor towards the target analyte. 
Essentially it is crucial for a bioreceptor to be selective and sensitive towards the specific 
target in order to prevent the interference by other substance from sample matrix [5]. Peptides 
have been used as components in biological analysis and fabrication of novel biosensors for a 
number of reasons, including mature synthesis protocols, highly selectivity for enzymes 
substrates and low production costs [1]. Bio-conjugation strategies can provide an efficient 
way to convert interaction information between peptides and analytes into a measurable 
signal, which can be used for fabrication of novel peptide-based biosensors [1]. Peptides are 
formed by natural or synthetic amino acids which are linked by peptide bonds with shorter 
lengths than those of proteins [1]. Peptides have the same building block as proteins, so they 
may be possible substitutes for proteins in biological analysis [1]. Peptides can be obtained 
by screening and optimization of artificial peptide libraries and they can provide high affinity 
to a specific target. In addition, they have a lot of advantages than proteins, including: high 
chemical and conformational stability, standard synthetic protocol, easy modification and 
large chemical versatility [1]. For all of these reasons they are chosen as capture agents in the 
development of our biosystems. Following the outline of the thesis is reported with a brief 
description of each chapter. The first part of the thesis presents an introduction to the 
principles of biosensors science and their potential applications in the food, agricultural 
industries and biomedical fields. Furthermore, peptides based biosensors are presented with a 
description of their properties, features and advantages. The use of peptides as capture agents 
and the possibility to exploit their reversibility in biological applications, despite proteins and 
antibodies, is still very limited and has not been addressed yet. This aspect has been 
investigated in this first chapter. In Chapter 2 microfluidic synthesis of novel polymeric 
microparticles endowed with specific peptide due to its superior specificity for target binding 
in complex media, is reported. In more details, a peptide sequence is efficiently encapsulated 
into the polymeric network and protein binding occurred with high affinity (KD 0.1-0.4 µM). 
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Fluidic dynamics simulation is performed to optimize the production conditions for 
monodisperse and stable functionalized microgels. The results demonstrate the easy and fast 
realization, in a single step, of functionalized monodisperse microgels using droplet-
microfluidic technique, and how the inclusion of the peptide within polymeric network 
improves both the affinity and the specificity of protein capture. In Chapter 3 the 
development of a peptide-based biosensor for autofluorescence aflatoxin M1 detection in a 
sensitive, specific and unsophisticated manner, is reported. To this aim an integrated 
approach has been developed to select specific peptide motif to capture aflatoxin M1. The 
integrated approach provides a combination of computation modeling with combinatorial 
peptide synthesis to screen the sequence with the highest affinity. Peptides sequences selected 
by the proposed approach have been easily co-polymerized in PEGDA microparticles 
opening the route towards a direct detection of aflatoxins in small volume both in liquid and 
solid environments. Such approach can be applied also to other small molecules to develop 
materials able to sequestrate the target analytes allowing their direct detection directly in the 
materials. Finally in Chapter 4 a microdevice for endometriosis diagnosis is developed. In 
this work, three different peptides (CRP-1, VEGF-114 and ΦG6) are used as capture agents 
to detect serum levels of vascular endothelial growth factor (VEGF), tumor necrosis factor-
alpha (TNF-a), and C-reactive protein (CRP): three serum markers of endometriosis in 
menstrual blood. The selected peptides have been covalently immobilized on a microfluidic 
PDMS device, previously derivatized with 10% of PAA (Poly(acrylic acid)) solution. The so 
built device has been used to capture and recognize endometriosis markers both in buffer and 
biologic fluids matrices such as human serum with a good specificity and sensitivity.  
So the aim of the studies in this work, is to set up miniaturized microdevices that can be used 
in healthcare and food industry, using peptides as capture agents in order to have sensitive but 
not invasive and not expansive biosensors.  
. 
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                                                                          Chapter 2 
  
Functionalized poly(ethylene glycol) diacrylate 
microgels by microfluidics: in situ peptide 
encapsulation for in serum selective protein detection 
 
ABSTRACT.  Polymeric microparticles represent a robustly platform for the detection of 
clinically relevant analytes in biological samples; they can be functionalized encapsulating a 
multiple types of biologics entities, enhancing their applications as a new class of colloid 
materials. Microfluidic offers a versatile platform for the synthesis of monodisperse and 
engineered microparticles. In this work, we report microfluidic synthesis of novel polymeric 
microparticles endowed with specific peptide due to its superior specificity for target binding 
in complex media. A peptide sequence was efficiently encapsulated into the polymeric 
network and protein binding occurred with high affinity (KD 0.1-0.4 µM). Fluidic dynamics 
simulation was performed to optimize the production conditions for monodisperse and stable 
functionalized microgels. The results demonstrate the easy and fast realization, in a single 
step, of functionalized monodisperse microgels using droplet-microfluidic technique, and 
how the inclusion of the peptide within polymeric network improves both the affinity and the 
specificity of protein capture. 
 
 
 
 
 
 
 
The work described in this Chapter has been submitted for publication: Giorgia Celetti, Concetta Di Natale, 
Filippo Causa, Edmondo Battista, Paolo A. Netti: “Functionalized poly(ethylene glycol) diacrylate microgels by 
microfluidics: in situ peptide encapsulation for in serum selective protein detection”.   
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2.1 INTRODUCTION 
 
In the recent years, hydrogels-based technologies has been widely developed for a range of 
biotechnology applications including diagnostic [1-3], drug delivery [4,5], and tissue 
engineering [6,7]. Due to their biocompatible and highly tunable nature they represent ideal 
candidates for biosensing applications. Their microstructure and interfacial proprieties can 
also be rendered responsive to various stimuli through chemical and physical cues resulting 
in “smart” materials which can respond to their local environment [9]. In particular, 
hydrogels can be engineer with different biological entities such as nucleic acids or peptides 
[5] for capture and detection of proteins, DNA, mRNA and microRNA [10]. Hydrogels are 
typically prepared and processed as bulk materials such as monolithic structures or supported 
films. However, emerging applications require miniaturization and tailoring of hydrogel 
architecture at increasingly small length scales for delivery and transport purposes in 
microscopic environments. This has spurred the development of various processes for the 
synthesis of colloidal and microparticle hydrogels, or “microgels” [9]. Hydrogel 
microparticles have been suggested as diagnostic tools for the rapid, multiplexed screening of 
biomolecules due to their advantages in detection and quantification [11-13]. Compared to 
traditional planar arrays, particle-based arrays offer easier probe-set modification, more 
efficient mixing steps, and higher degrees of reproducibility [14]. However appropriate 
methods for achieving the functionalization of large microparticles have not yet been 
developed [15].  
Among the various approaches for synthesizing hydrogel microparticles, microﬂuidics 
represent one of the most promising methods for the production and the functionalization of 
monodisperse microgels, including droplet microﬂuidics [16-18] and ﬂow lithography [18]. 
In particular, droplet microﬂuidics facilitates fabrication of spherical microparticles (i.e., 
microspheres) or microparticles with complex chemical compositions [18], and potentially 
enables higher throughput synthesis [19]. Prior reports have demonstrated the ability of 
microﬂuidic-based platforms to synthesize, functionalize and encode microparticles with 
multiple bioactive agents [18,20,21], in a single step, overcoming the conventional emulsion 
polymerization methods [9]. Here we present a novel droplet microfluidics method that 
allows an easy and fast functionalization of polymeric microparticles for selective 
biomolecules detection in complex biologic matrix. 
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Due to its biocompatibility and low-biofuling properties poly(ethylene glycol) (PEG) has 
been widely used for hydrogels particles-based assays [10]. Various approaches have 
explored PEG’s utility as biosensor platform including direct physical entrapment [22] or 
covalently linking the biomolecules  to the polymer network [23].  
Most of the validated detection strategies use monoclonal antibodies as target recognition 
moieties, however the use of these large macromolecules has several limitations, including 
poor stability and high production costs [24,25]. Contrariwise, small molecules like peptides 
can be prepared synthetically and mimic the antibody binding site by using only a small 
cluster of residues, even though with lower affinity and specificity toward biomolecule target 
[26]. Hydrogel networks endowed with bioactive peptides have been already reported for 
applications such as tissue engineering, where short peptide sequences were demonstrated to 
elicit specific cell functions or change the materials network upon specific cell responses 
[27]. However, the capability of hydrogel microparticles, functionalize with a small 
molecules in a single step, to increase the affinity and the specificity of a protein capture has 
not yet been explored.  
In this work, we use droplet microfluidics for one step synthesis of monodisperse and stable 
micrometer poly(ethylene glycol) diacrylate (PEGDA) hydrogels, in which label Strep-tagII 
peptide sequence was incorporated in order to create a functional microparticles for selective 
protein detection in complex fluid (Figure 1). Droplet-microfluidics was used to produce 
water in oil emulsion in which reactive and label peptide was included directly in flow, 
eliminating the need for costly and time-consuming labeling steps. Computational fluidic 
dynamics simulation (CFD) was used to optimize the design of the device investigating the 
parameters that influence droplet formation. After UV polymerization the capability of 
PEGDA-peptide microgels to detect Streptavidin protein in buffer and in complex biological 
medium was demonstrated by confocal and fluorescence spectroscopy methods. This tool-
system promises to be useful for producing a novel, efficient and sensitive polymeric 
microparticles to detect bio-molecular targets with higher affinity in complex medium. 
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Figure 2.1: Schematic representation of Strep-tagII microgels synthesis able to detect 
Streptavidin protein in human serum. Such approach includes: phase modeling; microfluidic 
fabrication and validation; and assay validation for selective protein detection. 
 
 
2.2 MATERIALS AND METHODS 
2.2.1 Materials   
Poly(ethylene glycol) diacrylate (PEGDA, 700 MW), the non polar solvent light mineral oil 
and the nonionic detergent sorbitan monooleate (Span 80) were purchased from Sigma 
Aldrich. Crosslinking reagent Darocur 1173 was purchased from Ciba. Reagents for peptide 
synthesis (Fmoc-protected amino acids, resins, activation, and deprotection reagents) were 
purchased from Iris Biotech GmbH (Waldershofer Str. 49-51 95615 Marktredwitz, 
Deutschland) and InBios (Naples, Italy). Solvents for peptide synthesis and HPLC analyses 
and Streptavidin ATTO-425 were purchased from Sigma-Aldrich; reversed phase columns 
for peptide analysis and the LC–MS system were supplied respectively from Agilent 
Technologies and Waters (Milan, Italy). Pooled human serum from healthy donors was 
supplied by Lonza (Life Technology Ltd, Paisley, UK). All chemicals were used as received. 
2.2.2 Microfluidic device 
Microfluidic device consists of two inlets for the continuous and disperse phase, a narrow 
orifice in which the main channel and the two opposite channels converge, and a serpentine 
in which droplets were polymerized. The dimensions of the device are 50 × 35 µm (width × 
depth) for the channels solutions, 35 × 35 µm at the junction (width × depth); the serpentine 
is 10 cm long. The microfluidic device was fabricated by combining the conventional 
photolithographic and soft-lithographic techniques. Briefly, negative photoresist (Mr-DWL 
40 phtoresist, Microresist technology) was spun onto a silicon wafer at 2000 rpm for 30 s to 
make a 35 µm thick layer of photoresist. Then, the photoresist was baked and subsequently 
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exposed using DWL 66 Fs LASER technology system (Heidelberg instruments). After the 
exposed sample had been post-baked and developed, the microfluidic flow focusing device 
master was prepared. The surface of the device mold was treated with tridecaﬂuoro-1,1,2,2-
tetrahydrooctyl-1-trichlorosilane to facilitate the peeling off of the polydimethyl-siloxane 
(PDMS, Sylgard 184, Dow Corning) replica. PDMS (10:1 polymer to curing agent) was 
poured on the patterned silicon wafer containing negative-channels. The PDMS-based 
microfluidic device was peeled off from the wafer and bonded on a glass slide with oxygen 
plasma treatment.  
2.2.3 CFD simulation 
To optimize the design of the device, computational fluid dynamics simulations were 
performed using COMSOL Multiphysics 4.2b software. During the simulation, all geometries 
were created two-dimensional based on the dimensions of the designed microfluidic device. 
A two-dimensional model was chosen to reduce complexity and computation time. The 
momentum and mass balances were modeled by Navier-Stokes equations and the level set 
method (LSM) was used to model the two phases. The principle on which LSM is based is 
the assignment of a so-called level set function Φ(x, t) to the space occupied by an interface, 
where x denotes the co-ordinates of a point within that space at a time t. The function is 
initialized at time t0, and then a numerical scheme is used to approximate the value of Φ(x, t) 
over small time increments, thus enabling the propagation of the interface to be tracked in 
time. The interface is represented by the zero contour of the level set function Φ. Φ > 0 on 
one side of the interface and Φ < 0 on the other. The level set function is chosen such that the 
position of the water–oil interface is described by the 0.5 contour of the level set function Φ 
and for Φ > 0.5 the break off occurs and the droplet is formed.(Dendukuri and Doyle 2009) 
Channel geometries were meshed using the free meshing tool and the channel walls were 
specified as wetted walls with a constant contact angle, measured experimentally using the 
instrument Contact Angle CAM 200. The interfacial tension between the continuous phase 
and the prepolymer solution was changed from 4.27 to 1.68 mN/m to investigate the 
influence of the surface tension (γ) on the droplet sizes. In particular, three prepolymer 
solutions of PEGDA (20, 40, 60 wt %) and three oil solutions (with 5, 10, 15 % of surfactant) 
were chosen and for each PEGDA/oil solutions γ was measured by pendant drop CAM 200. 
The viscosity of the two fluids was measured with 50 mm flat-plate geometry by rheometer.  
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2.2.4 Microgel synthesis 
Microgels were synthesized using light mineral oil containing nonionic surfactant Span 80 (5 
wt%) as a continuous phase and poly(ethylene glycol)diacrylate (PEGDA) (20 wt%) with 
photoinitiator (0.1 wt%) and Strep-tagII-FITC (0.5 mg/mL) as disperse phase. Droplet 
emulsions were formed injecting prepolymer solution, disperse phase, through the central 
channel and oil solution, continuous phase, through two opposite side channels. The uniform 
PEGDA-peptide droplets were crosslinked in flow to form monodisperse microgels. To 
photopolymerize droplets DAPI microscopy filter (9.8 mW, λ=360 nm) was used, focusing 
the UV light on the serpentine and regulating the diaphragm aperture of the microscope, for 
15 s. After photopolymerization, microgels were collected in an eppendorf and washed three 
times with a solution of ethanol (35 v/v%) and acetone (10 v/v%) to remove the oil. After 
washing, microgels containing Strep-tagII-FITC were analyzed by confocal microscopy. 
Polyethylene tubes were connected to the inlets and outlets and the solutions were injected 
using high-precision syringe pumps (neMesys-low pressure) to ensure a reproducible, stable 
flow. This system was mounted on an inverted microscope (IX 71 Olympus) and the droplets 
formation was visualized using a 4× objective and recorded with a CCD camera Imperx IGV-
B0620M.  
2.2.5 Peptide synthesis 
Strep-tagII-peptide ((WSHPQFEKD(OAll))) synthesis was performed on a fully automated 
multichannel peptide synthesizer Biotage® Syro Wave™. Preparative RP-HPLC was carried 
out on a Waters 2535 Quaternary Gradient Module, equipped with a 2489 UV/Visible 
detector and with an X-Bridge
TM
 BEH300 preparative 10× 100 mm C18, 5μm column. LC–
MS analyses were carried out on an Agilent 6530 Accurate-Mass Q-TOF LC/MS 
spectrometer. Zorbax RRHD Eclipse Plus C18 2.1 x 50 mm, 1.8 µm columns were used for 
the analyses. The Strep-tagII-peptide was synthesized in the acetylated/amidate version, 
employing the solid phase method on a 50 μmol scale following standard Fmoc strategies. 
Rink-amide resin (substitution 0.45 mmol/g) was used as solid support. Activation of amino 
acids was achieved using HBTU/HOBt/DIPEA (1:1:2). All couplings were performed for 
15 min and deprotections for 10 min. To monitor peptide entrapment, Lysine side chain 
amine fluorescein labeling was achieved by on-resin treatment with fluorescein 
isothiocyanate (FITC) after removing methyltrityl (Mtt) protecting group using 1% TFA in 
DCM for 30 min. Peptide was then removed from the resin, by treatment with a 
TFA/TIS/H2O (95:2.5:2.5, v/v/v) mixture for 90 min at room temperature; then, crude peptide 
was precipitated in cold ether, dissolved in a water/acetonitrile (1:1, v/v) mixture, and 
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lyophilized. Product was purified by RP-HPLC applying a linear gradient of 0.1% TFA 
CH3CN in 0.1% TFA water from 5% to 70% over 30 min using an X-Bridge
TM
 BEH300 
preparative 10× 100 mm C18, 5μm column at a flow rate of 10 mL/min. Peptide purity (95%) 
and identity (1488 amu) was confirmed by LC–MS (data not shown). Purified peptide was 
lyophilized and stored at −20 °C until use. 
2.2.6 Peptide encapsulation and characterization 
Peptide was encapsulated adding Strep-tagII-FITC (0.5 mg/mL) to the disperse phase prior to 
microgel synthesis. Fluorescent microgels without peptide, used as negative control, were 
obtained dissolved 0.1 mg of Rhodamine B in 10 mL of water solution. Fluorescence analysis 
was performed by Leica SP5 confocal microscope. Bright field and fluorescence images 
using a HCX IRAPO L 25×/0.95 water objective were acquired; 488nm line of the Argon 
laser as excitation sources for FITC-peptide was used and detection occurred at the 500-530 
nm band. Images were acquired with a resolution of 1024 × 1024 pixels, zoom 1, 2.33A.U. 
pinhole. All our experiments were performed at room temperature.  
 
2.2.7 CD analysis  
CD spectra were recorded using a JascoJ-1500 spectropolarimeter in a 1.0 cm quartz cell at 
room temperature. The spectra were recorded from 300 to 190 nm, with a band width of 1 
nm, a time constant of 16 s, and a scan rate of 10 nm/min. Spectra were recorded subtracting 
them from blank samples.  
2.2.8 Streptavidin Atto-425 binding and characterization 
Binding experiments were performed incubating Strep-tagII-microgels and microgels without 
peptide (Control-microgels) with Streptavidin-Atto-425 (peptide/protein ratio 5/1) in PBS 
(pH 7.4) and human serum from healthy donors (final volume 200 mL) at room temperature 
for 2 h. After incubation Strep-tagII-microgels and Control-microgels were centrifuged for 5 
min at 10000 rpm and the supernatant was measured by fluorescence spectroscopy (λ exc 436 
– λ em484) using a Perkin Elmer 2300 Enspire Plate Reader. 
To demonstrate the ability of our system to detect specific protein, 100 µL of Strep-tagII-
microgels were suspended in 1 mL of PBS and different concentrations of Streptavidin 
protein, ranging from 0.16 µM to 1.6 µM (Figure S4), were added and these solution were 
incubated for 2 h. After the incubation, microgels were washed three times and their 
fluorescence was analyzed. The same protocol was used for microgels without peptide, as a 
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negative control, and for Strep-TagII-microgels in serum analysis as well. Fluorescence 
analysis was performed by Zeiss LSM700 confocal microscope. For this experiment 20× dry 
objective was used. Two-channel fluorescence images, simultaneously, using multitrack 
mode were acquired. 480 nm and a 405 nm DAPI solid state lasers as excitation sources were 
used for peptide-FITC and Streptavidin-Atto-425-protein 435, respectively. Their detection in 
fluorescence was 500-530 nm and 410-450 nm bands, respectively.  
2.2.9 Statistical analysis 
The results of confocal experiments were analyzed by software GraphPad Prism version 5.04 
and experimental data were expressed as mean ± standard deviation. One-tailed analysis of 
variance with an Unpaired t-Test was performed to compare all experimental groups and to 
determine statistical significance of p < 0.05. The evaluation of KD was calculated by a non-
linear fitting approach using GraphPad Prism version 5.04 software. 
 
2.3 RESULTS AND DISCUSSIONS 
2.3.1 Microfluidic design 
Microfluidic design, showed in Figure 2.2, is optimized to obtain monodisperse and stable 
functionalized microgels in order to create a tool-system for diagnostic and sensing. Droplet 
formation process is affected by several physical parameters such as flow rates, viscosity of 
the fluid, dimensions of the geometry, capillary number (Ca) and surface tension [28]; 
therefore, the design of optimal microfluidic device for the production of monodisperse and 
stable emulsion relies on controlling such parameters.  
 
Figure 2.2: Microfluidic flow-focusing device. Scale bar are 100 µm. 
 
In the first set of simulations the influence of geometry and Ca on droplet production was 
investigated. Firstly the dimensions of the junction were changed; in particular, different 
widths (25, 30, 35 and 40 µm) and lengths (50, 100 and 500 µm) were modeled. These 
studies revealed that monodispersity and stability of droplets can be ensured choosing 
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junction geometry appropriately, maintaining the flow rate constant. Based on the simulation 
results, junction size of 50 × 35 × 50 µm (width × depth × length) was chosen. 
Droplet formation is driven by the competition between the viscous stress and the surface 
tension of two immiscible fluids, and occurs at a critical Capillary number (Ca), Ca=µU/γ 
[29]. For this reason, the influence of Ca on emulsion stability was investigated, maintaining 
the dimensions of the device constant. Ca can be modified by varying the flow rate of the 
continuous phase (Qoil); a diagram of flow patterns was used to investigate on stable droplet 
formation (Figure 2.3). Simulation results shows three different flow patterns after the 
junction: elongation flow pattern, stable emulsions and unstable emulsions (Figure 2.3 A, 2.3 
B, 2.3 C).  
          
Figure 2.3: Flow diagram as function of PEGDA prepolymer flow rate (Qp) and capillary 
number (Ca). Three distinct regions were observed: a) elongation flow of thread, b) stable 
droplets, c) unstable droplet formation. 
 
It is difficult generate stable emulsion at high flow rates of prepolymer solution (Qp > 8×10
-2
 
µl/min) (Figure 2.3); in fact, W/O emulsion could not separate uniformly from the junction 
due to the unstable hydrodynamic pressure of PEGDA prepolymer phase. When the flow of 
the oil phase relatively increases, the flow of prepolymer solution reverses into channels. 
When the value of Ca is in a limited range 0.005 ~ 0.055 and the value of PEGDA flow rate 
is between 3×10
-2
 µl/min and 8×10
-2
 µl/min, the prepolymer phase breaks into a stable 
emulsions (regime of stable emulsions Figure 2.3B). Choi et al. also investigated on the flow 
patterns to obtain stable polymeric droplets [30]. They found that stable and monodisperse 
emulsions were generated in a limited range of Ca (0.5×10
-2
~ 0.5×10
-1
) and a flow rate of 
disperse phase (0.2~1.1 µL/min). it is higher than the flow rate chosen in our simulation due 
to the different channels dimensions. 
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Precise control of particle size and monodispersity are critical for many applications of 
microgels; microfluidic platform allows this control over a wide range of sizes [31]. For this 
reason, in the second set of simulations the influence of Qoil on the droplet size was 
investigated, while Qp was kept constant. Once the dimensions of the device had been fixed, 
microgels with a wide range of sizes, ranging from 10 to 90 µm, were produced. Droplets 
diameter was calculated during the simulation analysis. In particular, droplet size was 
determined by the flow rates of the two phases and the flow rate ratio, as proposed by Collins 
et al. Therefore, maintaining the ratio of the disperse and the continuous phase flow rates 
appropriate [30], droplets size decreased as Qoil increased. In order to stabilize droplets 
against uncontrolled coalescence, the use of a surfactant is necessary. These molecules 
populate the water/oil interface and prevent droplet coalescence. In emulsification processes, 
the effect of the interfacial tension on droplet size and stability is significant [32, 33]. For this 
reason, we investigated on the influence of the surface tension (γ); in particular, γ was 
changed from 4.27 to 1.68 to mN/m (Figure 2.4) and it was observed that when γ increased, 
droplets diameter increased (Figure 2.5).  
                       
Figure 2.4: The measures of surface tension between PEGDA prepolymer solution (20, 40, 60 
wt %) and oil solution (with 5, 10, 15 % of surfactant) by pendant drop CAM 200 were 
showed. With increase of the concentration of the surfactant (Cs) the surface tension 
decrease. The surface tension depends also on the PEGDA concentration, in particular 
increasing PEGDA concentration the surface tension decrease. 
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Figure 2.5: The mean diameter of generated microgels as a function of surface tension. 
Simulation results of 3 groups of cases with various values of interfacial tension: (a) 1.6 
mN/m, (b)2.3 mN/m, (c) 4.2 mN/m, at different Qpeg. 
 
Another parameter that influences the viscosity and, consequently, the interfacial tension 
between the two phases is the polymer concentration in water solution. A solution with 
prepolymer concentration lower than 20 wt % can be used to form droplets, but UV curing 
requires long time and these droplets could be display deformation and loss of mechanical 
stability under flow conditions [10]. Instead, a solution with PEGDA concentration higher 
than 60 wt % can be cured by UV light in less time; however, it is difficult to control the 
stability of the droplets because of its high viscosity [34]. For this reason, a prepolymer 
solution at 20 wt.% of PEGDA was used and the length of the serpentine at 10 cm was 
optimized to ensure droplet polymerization.  
 
2.3.2 PEGDA-peptide microgels synthesis and characterization 
Here microfluidic synthesis of biodegradable PEGDA-peptide microgels for diagnostic 
applications is reported. The encapsulated peptide is Strep-tagII, an eight amino acid peptide 
(H2N–WSHPQFEK–COOH) selected from a random peptide library as an artificial ligand for 
streptavidin protein [35]. It is usually used for efficient protein purification in a simple single 
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step and -because of its independence from metal ions- it is also important in the study of 
metallo-proteins [36]. Microgels synthesis is shown in Figure 2.6 A and described in 
Experimental Section. Briefly, the pre-polymer solution containing peptide Strep-tagII-FITC 
was injected through the central channel of the microfluidic device, as disperse phase, and oil 
solution with surfactant through its two opposite side channels, as continuous phase. Under 
optimized flow rate conditions, estimated by CFD simulation, disperse phase was sheared 
into monodisperse droplets by continuous phase. The amount of embedded peptide was 
calculated to be 50 µg in 100 µL of microgels (data not show). Based on flow conditions, the 
yield of microgel production was around 300 microgel/minutes. 
With regards to the homogeneity of microgels size and the peptide encapsulation, 
microfluidic set up allows robust and rapid synthesis of functionalized and uniform polymeric 
microparticles in a single step, overcoming the limits of the conventional suspension 
polymerization methods. Strep-tagII-microgels obtained are monodisperse in size with a 
coefficient of polydispersity (PDI) < 0.003 and peptide encapsulation was confirmed by 
confocal image (Figure 2.6). Despite the addition of such biologics may lead to a slight 
increase in the deviation of diameter, the resulting microgels remained largely uniform, 
thereby demonstrating the ability of our approach to encapsulate biomolecules in polymeric 
microparticles.  
                                    
 
Figure 2.6: PEGDA-peptide microgel (20%PEGDA, 0.1%Darcour,0.5mg/ml peptide).  
A) StreptagII microgels synthesis by microfluidic device. B) Size distribution of PEGDA-
peptide peptide microgels. C) Fluorescent image of StreptagII FITC encapsulation. D) Phase 
contrast image of microgels. Scale bare are 100µm. 
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PEGDA has been chosen for its advantages over other polymers and its specific proprieties, 
such as good biocompatibility, non-toxicity, low immunogenicity in vivo, and resistance to 
protein adsorption. Moreover, polyethylene glycol (PEG) hydrogels are widely used in 
biomedical fields such as drug delivery and tissue engineering [37, 38]. 
Finally, to verify the secondary structure of the peptide in solution and inside the microgels 
circular dichroism (CD) was performed. CD spectra of peptide registered in aqueous buffer 
solution (Figure 2.7A) revealed a random coil content due to the absence of Cotton bands at 
205, 222 nm that are typical of helix conformations. As showed in Figure 2.7A the addition 
of different TFE concentrations results in an increase of helical content, in particular at 60% 
of TFE peptide spectrum shows a presence of little Cotton bands at 205 and 222 nm. The 
same experiments were carried out for peptide incorporated into the microgels. CD data 
confirmed that Strep-tagII peptide retains its structure (random-coil as it expect for small 
peptides) after its encapsulation, as previously reported for other peptides [39, 40]. Figure 2.7 
B shows CD spectrum of Step-tagII peptide and Strep-TagII microgels. In order to analyze 
the structural behavior of the peptide encapsulated into the microgels, CD spectrum at 60% of 
TFE was recorded. In contrast of peptide spectrum at 60% of TFE, peptide encapsulated 
didn’t change its conformation even with high TFE content, showing only a slight band at 
220nm. Figures 2.7 C and D show CD data of Strep-tagII-microgels recorded at 0 and 60% of 
TFE and peptide spectrum in solution and incorporated inside microgels at the same TFE 
concentration.                                                                               
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Figure 2.7: CD analysis of Strep-tagII peptide and Strep-tagII peptide-microgels, in 
phosphate buffer 10 mM pH 7. Overlay of Strep-tagII peptide CD spectra recorded (A) with 
increasing amounts of TFE (from 0 to 60%), Overlay of StreptagII-peptide and StreptagII-
microgels CD spectra  in buffer solution (B), Overlay of StrepTagII microgels CD spectra 
recorded (C) with 0% and 60% of TFE and Overlay of StrepTagII peptide and microgels 
recorded  (D) with 60% of TFE.  
 
Because of the uniformity of the microgels diameter and the homogeneity of the peptide into 
the microgels, this approach may serve as a consistent method for selective protein detection. 
Importantly, our strategy is relatively simple and robust, and encapsulated molecules retain 
their structure during microgels processing. Moreover, we demonstrate that CFS allows a 
robust control over microgels synthesis, avoiding fabrications of many different microfluidic 
devices. 
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2.3.3 Protein-binding analysis in PBS and human serum 
One motivation for using peptide-binding proteins in polymeric networks is employ them as 
platform to have a selective protein detection in complex mixtures [41]. Protein-binding 
peptide is described in Experimental Section with more details. It occurred adding to Strep-
tagII-microgels different concentrations of Streptavidin protein, ranging from 0.16 µM to 1.6 
µM. Figure 2.9B shows Streptavidin-Atto-425 fluorescence on Strep-tagII- microgels after 2h 
of incubation at room temperature in PBS. The selective binding of our system was 
demonstrated using the same protocol for Control-microgels labeled with Rhodamine B 
(Figure 2.8 E). Atto-425 fluorescence signal occurred only on Strep-tagII-microgels and its 
intensity increased with increasing protein concentration (Figure 2.8 L), giving a reasonable 
specific binding signal. It is evident that Streptavidin-Atto-425 recognition is specific and 
dose-response on Strep-tagII-microgels, unlike Control-microgels (Figure 2.9 A), with an 
estimated KD of 0.40±0.11 µM, which demonstrate a good affinity toward Streptavidin 
protein. As reported the maximum constant affinity between such peptide and protein is about 
70 µM [42, 43], therefore microgel is able to improve the sensitivity and specificity of protein 
detection. Furthermore we assumed an uniform distribution of bound protein on microgels 
and a saturation point at 1.6 µM (Figure 2.9). Limit of detection of 0.2 µM is obtained with 
about 3.6 × 10
3
 particles in 100 µL of volume reaction. Indirect-assay, performed by 
spectrofluorometer, confirmed the ability of Strep-tagII-microgels to recognize Streptavidin, 
unlike Control-microgels (Figure 2.10).  
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Figure 2.8: Fluorescence detection of specific and unspecific binding both in PBS and in 
human serum. Single component detection: (A) strep-tagII-microgels (green) and (B) 
Streptavidin binding microgels (blue); (C) Overlay image. The single component images 
demonstrate that there is no occurrence of overlapping signals. (D) PEGDA microgels 
labeled with Rhodamine B (red) as a control of unspecific signal; (E) fluorescence image of 
streptavidin on control microgels; (F) overlay channel; (G) Strep-tagII-microgels (green) and 
(H) Streptavidin binding microgels (blue) in human serum; (I) Overlay image for specific 
protein-binding peptide in human serum; (L) Bioassay system efficiency of microgels-
bounding; (M) Performance of bioassay system for protein detection in PBS and in human 
serum. The binding event is detected by measuring the fluorescence intensity of Atto-425 
conjugated Streptavidin directly on 50 microgel particles. Statistical difference between Strep 
tag II-microgels and control microgels *p<0.05 (mean±SD n=2) in PBS and *p>0.05 
(mean±SD n=2) in human serum. 
Since most of the interesting proteins are located in biological complex matrices such as 
human serum, we evaluated the accuracy of our system directly in biological environment. 
Fluorescence image (Figure 2.9H) confirms the protein-binding peptide and the accuracy of 
the microgel-based assay also in complex matrix. Moreover Figure 2.10B shows that the 
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fluorescence intensity of the Streptavidin-Atto-425 is dose-responsive and specific in serum 
as well, with a KD of 0.12±0.047 µM [44-46]. Such performance is ascribable to the 
capability of the polymeric network to offer antifouling properties, thus improving the 
specificity of the capture.  
                   
Figure 2.9: Strep-tagII-microgels-protein binding confocal results. (A) the Streptavidin-
ATTO-425 recognition (red curve) is specific, unlike Control-microgels (black curve) 
(mean±SD n=2). (B) Comparison of confocal binding by non linear fitting in buffer (red  
curve) and in serum (blue curve). 
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Figure 2.10: Fluorescence spectroscopy binding assay between Strep-tagII-microgels and 
Streptavidin-Atto 425 protein. Different amount of unbound protein, ranging from 0.16 to 
1.6uM, were collected and analyzed by spectrofluorometer (λ exc 436 – λ em484). The fraction 
of bound protein reported was calculated by subtracting the emission of the unbound protein 
to total one. Inset the tritation curve of Streptavidin-Atto 425 used for the total protein 
fluorescence calculation. The differences in the amount of bound protein between Strep-tagII-
microgels (dark grey) and Control-microgels (light grey) were underlined by a lack of a 
specific binding in the control one. 
With our approach we synthesized “smart” microgels for selective protein detection both in 
PBS and in complex fluid, using droplet-microfluidics. This method is relative simple, rapid 
and support the use of the microfluidic device as a manufacturing platform for diagnostic use. 
We believe that the reported system can be broadly applicable for rapid synthesis of 
microgels for different application like biosensing or food and environmental contaminants 
detection, using different biopolymers and small molecules. 
2.4 CONCLUSIONS 
In conclusion, here we report droplet-microfluidics method for the easy and rapid synthesis of 
biodegradable PEGDA-peptide microgels for selective biomolecules capture in complex 
medium, unlike conventional techniques. Based on numerical simulations, we fabricate 
microfluidic device to produce stable and monodisperse microgels. Uniform distribution of 
the specific peptide within the microgel was achieved and the efficiency of peptide-to–protein 
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binding both in PBS and human serum was confirmed. The use of microfluidic platform 
easily leads the control on size, shape, and chemical proprieties of microgels as well as on the 
content and distribution of the encapsulated peptide. Such peptide-functionalized 
microparticles allows the enhancement of binding affinity and the specificity in complex 
media. About this point it is very important to modulate the peptide density into microgels, in 
order to avoid proteins crowding or to leave many gaps using very low peptide concentration. 
So the amount of  integrated peptide plays a strong and a limiting role in the affinity studies. 
Our system is easy and flexible towards the detection of different molecules, does not require 
additional reagents and allows for the specific detection in complex media because of its 
antifouling properties. The control of physical and chemical properties of polymeric 
microparticles obtained by droplet microfluidic, the hydrophilic characteristics and the 
flexibility of the molecular encapsulation of proposed microgel represent a modular platform 
that can be generalized for any direct bio-detection in complex media, and, thus, applied to a 
wide spectrum of biomedical applications. 
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                                                                          Chapter 3 
 
Miniaturized peptide-based biosensor for Aflatoxin M1 
in milk samples: from Peptide Screening to Biosensor 
Development. 
ABSTRACT. Mycotoxins are fluorescent low-molecular-weight natural products produced 
as secondary metabolites by fungi in milk and dried fruits. These metabolites are chemically 
stable molecules that cause disease and death in human beings [1]. In particular, they are 
teratogenic, mutagenic, nephrotoxic, immunosuppressive and carcinogenic. They are highly 
resistive in nature and hence remain in the food chain. Therefore, a rapid, sensitive and 
specific assay technique is required for the routine analysis of foods, and beverages. Current 
analytical determination includes immuno-and bio-luminescent assays, HPLC (fluorescence 
detection), TLC, gas and liquid chromatography coupled to mass spectroscopy [2]. However 
all of them present high costs and skilled quality control operators. Our idea is to develop a 
peptide-based biosensor for aflatoxin M1 detection in a sensitive, specific and 
unsophisticated manner. To this aim an integrated approach has been developed to select 
specific peptide motif to capture aflatoxin M1. The integrated approach provides a 
combination of computation modeling with combinatorial peptide synthesis to screen the 
sequence with the highest affinity. In particular,   computation modeling using a C-docker 
alghoritm was performed to determine the Binding energy of all possible peptide 
combinations against toxin, using as building blocks eight different amino-acids chosen by 
considering their different chemical properties. The combinatorial peptide libraries were 
obtained with the same building blocks and best alfatoxin binders were selected by SPR 
(Surface Plasmon Resonance). Peptides sequences selected by the proposed approach have 
been easily integrated in PEGDA microparticles opening the route towards a direct detection 
of aflatoxins in small volume both in liquid and solid environments. Such approach can be 
applied also to other small molecules to develop materials able to sequestrate the target 
analytes allowing their direct detection directly in the materials. 
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3.1 INTRODUCTION 
Mycotoxins are low-molecular-weight natural products (i.e., small molecules) produced as 
secondary metabolites by filamentous fungi. These metabolites constitute a toxigenically and 
chemically heterogeneous assemblage that are grouped together only because the members 
can cause disease and death in human beings and other vertebrates. Not surprisingly, many 
mycotoxins display overlapping toxicities to invertebrates, plants, and microorganisms [1]. 
The term mycotoxin was coined in 1962 in the aftermath of an unusual veterinary crisis near 
London, England, during which approximately 100,000 turkey poults died. This mysterious 
turkey X disease was linked to a peanut (groundnut) meal contaminated with secondary 
metabolites from Aspergillus flavus (aflatoxins) [1]. 
Mycotoxins are not only hard to define, they are also challenging to classify. Due to their 
diverse chemical structures and biosynthetic origins, their myriad biological effects, and their 
production by a wide number of different fungal species, classification schemes tend to 
reflect the training of the person doing the categorizing. Clinicians often arrange them by the 
organ they affect [3]. Thus, mycotoxins can be classified as hepatotoxins, nephrotoxins, 
neurotoxins and immunotoxins [4]. Cell biologists put them into generic groups such as 
teratogens, mutagens, carcinogens, and allergens. Organic chemists have attempted to 
classify them by their chemical structures (e.g., lactones, coumarins); biochemists according 
to their biosynthetic origins (polyketides, amino acid-derived,etc.); physicians by the illnesses 
they cause (e.g., St. Anthony’s fire, stachybotryotoxicosis), and mycologists by the fungi that 
produce them (e.g., Aspergillus toxins, Penicillium toxins) [1].  
Currently, more than 300 mycotoxins are known, but most of studies are focused on 
aflatoxins, ochratoxin, trichothecenes, zearalenone and fumonisin [5]. The synthesis of 
mycotoxins occurs during different stages of food production, and in particular, they are 
found in the growing and storage. They can cause several pathologies in animals and people. 
Aflatoxins, for example, cause liver damage, decreased production of milk and eggs and 
immune deficiency in animals which have consumed low amounts of contaminated food 
without any obvious clinical manifestations. Typical clinical signs are: gastrointestinal 
dysfunction, reduced reproduction, loss of appetite and anemia [6,7]. Aflatoxins are a group 
of toxins furanocoumarins polyketides produced by certain species of Aspergillus and their 
most toxic and carcinogenic member is the aflatoxin B1. By reported cases seems that the 
mold Aspergillus is diffused in warmer climates, and the optimum temperature for its growth 
is 30°C but it can also grow in a temperature range between 10°C and 45°C.  
 56 
 
Numerous types of aflatoxins have been identified but the most important are: the aflatoxin 
B1, B2, G1, G2 and their metabolic derivatives M1 and M2 present in particular in the milk 
of animals that have ingested contaminated food [8]. 
The metabolism of AFB1 is determined primarily by cytochrome P450 (CYP450). Typically 
isoforms CYP1A2 and CYP3A4 are the most involved in the activation of AFB1 with the 
formation of the 2,3 epoxide responsible for binding with nucleic acids and the subsequent 
activity on protein synthesis and hepato-carcinogenic function (Figure 3.1). The AFM1 
derives its name from "milk" and it is the unique AFB1 metabolite that passess in significant 
quantities in milk; However, it is also present in other body fluids (blood and urine), as well 
as in organs such as liver and kidney. 
                              
      Figure 3.1: Mechanism of AFM1-DNA binding [8]. 
 
It is formed by aflatoxin B1 through a process of hydroxylation in the liver and kidney and is 
subsequently eliminated in the milk, while a small portion is deposited in the muscle. The 
AFM1 in milk begins to appear after about 12 hours from start of administration of 
contaminated food. The toxic effect is due to the toxin-nucleic acids and toxin-nucleoproteins 
binding, and the result is a weakening of the immune system, carcinogenicity and 
teratogenicity (birth defects). AFM1 food limits are regulated by Normativa 10 del 9-6-99; 
recepimento Reg.CEE 1528/98 as follows: 
• Milk products 0.05 ppb (50 ppt). 
• Infant food 0.01 ppb. 
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Most of the mycotoxin are molecules chemically stable that remain unchanged during storage 
and production. The best strategy to control the mycotoxin presence in the food chain is the 
prevention. Low molecular weight mycotoxins possess a variety of chemical structures which 
is the main constraint to develop one standard technique for analysi. There has been a major 
international research effort, aimed at the identification and quantification of mycotoxins and 
evaluation of their biological effects in humans and animals [3].  
Conventional techniques used for the detection of mycotoxins 
The analytical determination is important for the evaluation of toxins: immuno-
chemiluminescent and bioluminescent assays are generally used for the analysis of 
mycotoxins. Currently, however, the most used techniques for the determination of 
mycotoxins are chromatographic ones: HPLC (fluorescence detection), TLC, gas and liquid 
chromatography coupled to mass spectroscopy [2], (Figure 2.1). Also the comparison of 
genomic DNA sequences can be used for the identification of the fungal species responsible 
for the synthesis of mycotoxins and this cDNA can also be useful to determine if the genes 
for the biosynthesis of these molecules are expressed in a specific way or not. 
The determination at molecular level is carried out by: PCR and RT-PCR. Another method 
used for the detection of toxins is the ELISA assay. In this assay, the wells of the plate 
containing an antibody against these toxins. The detection reagent is a covalent complex 
between the mycotoxin and an enzyme, usually horseradish peroxidase or alkaline 
phosphatase. ELISA typically uses a fluorimetric or colorimetric method for the detection. 
However, substrates may also be used with products that can be measured electrochemically; 
in this case the immunoreagent are immobilized on the surface of an electrode. The 
advantage of electrochemical assays is the low cost of production of the electrodes. 
Applications based on these types of assays have included the detection of AFM1 in milk [9], 
AFB1 in barley and rice  [10,11] and OTA in wheat [12]. Though these methods are well 
known for their accurate and precise detection of mycotoxin in  food or feed samples, they 
require skilled operators, extensive sample pretreatment, equipment and may lack accuracy at 
low analyte concentration [13,14]. Therefore, a rapid, sensitive and specific assay technique 
is required for the routine analysis of foods, and beverages.  
The biosensors are instruments that use biological molecules, such as antibodies or enzymes, 
which come into contact with a substance, such as a toxin, react and undergo changes which 
are then "translated" into a measurable electrical signal or impulse. These devices have an 
high sensibility, high selectivity, low cost, offering the chance to be reborn and have many 
potential applications. Biosensors can be easily used in the food industry to determine the 
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presence of mycotoxins in food [15]. Among the most widely used for this purpose there are: 
the piezoelectric biosensors (simple, rapid and highly selective) and microarray 
(simultaneous detection of molecules with high, medium and low molecular weight). Over 
the last few years the use of "Lateral flow tests" also increased. The lateral flow tests are 
simple devices designed to detect the presence (or absence) of a target analyte in the sample 
(matrix) without the need for specialized, expensive equipment; one of the most recent used 
for the detection of aflatoxin M1 was designed by the CHARM. It is the only lateral flow test 
that detects the presence of aflatoxin M1 in parts per trillion (ppt) in raw milk. It is designed 
to respect the U.S.A. FDA limit of 500 ppt (0.5 ppb). 
      
 
      Figure 3.2: HPLC detection of AFM1 in raw milk (advantages and disadvantages). 
In this work we described a miniaturized peptide-based biosensor for rapid, sensitive and 
specific detection of Aflatoxin M1 in complex milk samples. To this aim we developed an 
integrated approach to select specific peptide motif to capture aflatoxin M1. The integrated 
approach provides a combination of computation modeling with combinatorial peptide 
synthesis to screen the sequence with the highest affinity.  In particular, computation 
modeling using a C-docker alghoritm was performed to determine the Binding energy of all 
possible peptide combinations against toxin, using as building blocks eight different amino-
acids chosen by considering their different chemical properties.  The combinatorial peptide 
libraries were obtained with the same building blocks and best alfatoxin binders were 
SAMPLE PREPARATION 
Reconstitute sample if 
necessary. 
Centriguge. 
Separate fat from skim. 
AFFINITY CHROMATOGRAPHY 
Pass skim milk over affinity column. 
Wash column with water. 
Elute Aflatoxin M1 from column with 
CH3CN/CH3OH and collect eluate in a 
cuvette. 
MEASURE AFLATOXIN M1 
Inject eluate into HPLC. 
         
         SENSITIVE METHOD 
                        BUT 
•  TOO EXPENSIVE 
• TIME CONSUMING 
•  EQUIPPED 
LABORATORIES 
•  TRAINED WORKERS 
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selected by SPR (Surface Plasmon Resonance). Peptide sequences selected by proposed 
approach were easily integrated in PEGDA microparticles through a droplet microfluidic 
strategy in order to open the route towards a direct detection of aflatoxins in small volume 
both in liquid and solid environment. Droplet-microfluidics was used to produce water in oil 
emulsion in which reactive peptide was included directly in flow, eliminating the need for 
costly and time-consuming labeling steps. Computational fluidic dynamics simulation (CFD) 
was used to optimize the design of the device investigating the parameters that influence 
droplet formation. After UV polymerization the capability of PEGDA-peptide microgels to 
detect Aflatoxin M1 in buffer and in complex milk medium was demonstrated by confocal 
spectroscopy. This tool-system could be useful for producing a novel, efficient and sensitive 
peptide integrated microparticles to detect bio-molecular targets with higher affinity in 
complex medium. Our approach could be also applicable to other small molecules or 
contaminants whose sensitive detection is indispensable for food, biochemical or medical 
applications. 
 
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials    
Poly(ethylene glycol) diacrylate (PEGDA, 700 MW), the non polar solvent light mineral oil 
and the nonionic detergent sorbitan monooleate (Span 80) were purchased from Sigma 
Aldrich. Crosslinking reagent Darocur 1173 was purchased from Ciba. Reagents for peptide 
synthesis (Fmoc-protected amino acids, resins, activation, and deprotection reagents) were 
purchased from Iris Biotech GmbH (Waldershofer Str. 49-51 95615 Marktredwitz, 
Deutschland) and InBios (Naples, Italy). 1-ethyl-3-(3-dimethylaminopropyl)car-bodiimide 
hydrochloride(EDC) ,N-hydroxysuccinimide(NHS aflatoxinM1 (AFM1) and the conjugate of 
AFM1 with bovine serum albumin(BSA–AFM1) were fromSigma-Aldrich. Solvents for 
peptide synthesis and HPLC analyses were purchased from Sigma-Aldrich; reversed phase 
columns for peptide analysis and the LC–MS system were supplied respectively from Agilent 
Technologies and Waters (Milan, Italy). All SPR reagents and chips were purchased from 
AlfaTest (Rome, Italy ). All chemicals were used as received. 
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3.2.2 Peptide Synthesis 
Peptide libraries and single peptides were prepared by the solid phase method on a 50 μmol 
scale following the Fmoc strategy and using standard Fmoc-derivatized amino acids. Briefly, 
synthesis were performed on a fully automated multichannel peptide synthesizer Biotage® 
Syro Wave™. Rink amide resin (substitution 0.71 mmol/g) was used as solid support. 
Activation of amino acids was achieved using HBTU-HOBt-DIEA (1:1:2), whereas Fmoc 
deprotection was carried out using a 40% (v/v) piperidine solution in DMF. All couplings 
were performed for 15 minutes and deprotections for 10 minutes. For peptides library; 8 
different amino acids were chosen to build the library based on their chemical and physical 
properties. The selected amino acids for the library construction were Arg, Asn, Pro, Trp, 
Leu, Ala, Asp and Thr. The resin (4,55g) was split into 64 different tubes and each reactor 
holds the combination of the eight amino acids, selected for the library construction, as first 
and second coupling. At the end of coupling procedures previously reported, we obtained 64 
different di-peptides that constituted the first peptide library. The di-peptide with the best 
binding properties (selected by SPR technique) was chosen for the second library as  two 
fixed amino acids present at the C-terminal of the new tetrapeptide library . Thus we split   
the dipeptide resin into 64 different tubes and we bound the third amino acid to the  amine 
group of the second amino acid. At the end the fourth amino acid was linked to the third one 
by the same synthesis procedures. We obtained a second library composed by 64 
tetrapeptides that have the same two amino acids at the C-terminus but the first two amino 
acids at the N-terminal are randomized with eight different building blocks . The best binding 
tetra-peptides, selected by SPR, were functionalized with rhodamine to monitor their 
entrapment in microparticles. Lysine side chain amine rhodamine labeling was achieved by 
on-resin treatment with rhodamine isothiocyanate (TRITC) after removing methyltrityl (Mtt) 
protecting group using 1% TFA in DCM for 30 min. 
3.2.3 Computer Modeling 
Modeling and docking studies were conducted with software package Discovery Studio 
version 4.5, (BIOVIA 5005 WateridgeVista Drive, San Diego, CA 92121,USA). 
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3.2.3.1 The aflatoxin M1 structure .  
The first part of the work was to determine the structural conformation of the aflatoxin M1 
molecule. A search was executed in the Protein Data Bank (PDB) for structures which 
contain the aflatoxin M1 molecule. Several molecules were found  with the AFB1 -8, 9-exo-
epoxide bound to a DNA chain; however none contained the aflatoxin M1 molecule alone. 
Since no structure of the aflatoxin M1 molecule was available,  we tried to design it, through 
the Discovery Studio software with “Sketch and Edit molecules tools”. Aflatoxin M1 does 
not contain any chiral centres. The molecule was then charged by CharMm method and 
molecular mechanics was applied to minimized structure using the We perfomed 200 steps of 
energy minimization using the "Smart Minimizer algorithm" which performs Steepest 
Descent, followed by Conjugate Gradient minimization. In figure 3.3 the Aflatoxin M1 
sketched structure was reported. 
                       
Figure 3.3: Aflatoxin M1 sketched structure by “Sketch and Edit molecules tools”. 
3.2.3.2 Library design. 
The dataset for the monomers was set using a customized protocol to build peptides of a 
given length   developed through the Pipeline Pilot software (version 9.5) following the 
scheme showed in figure 3.4. Only 8 amino acids, selected on the basis of their chemical 
properties, were used as building blocks of the library (A,T,D,N,R,P,W,I). The generated di-
library was validated using a computational approach composing by molecular dynamics, 
docking algorithms and binding energy estimation.   The docking procedure was used to 
obtain a scoring of the best di-peptide binding sequences, against the target toxin, that were 
used as start point to generate another tetra-peptide library using the same amino-acids, 
previously mentioned, as building blocks. All 64- tetra-peptides generated were validated 
again by the same computational approach.. 
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Figure 3.4: Flow chart of the protocol implemented in the Pipeline Pilot software used in this 
work to generate di- and tetra- peptide library. 
 
 
3.2.3.3 Molecular dynamics simulation and C-docker procedure 
All the 64 peptides of the di-and tetrameric library were typed with CHARMn (Biovia) force 
field. We perfomed 200 steps of energy minimization using the "Smart Minimizer algorithm" 
which performs Steepest Descent, followed by Conjugate Gradient minimization. Minimized 
peptide structures were solvated inside an orthorombic water box ionized with a 0.145 M salt 
concentration. We performed molecular dynamics simulation of the solvated peptides using 
the following protocol: an initial minimization stage using 1000 steps of Steepest Descent 
algorithm, a second minimization stage 2000 steps of Conjugate Gradient method, an 4 ps 
heating stage to increase the temperature from 50 K to 300 K, a 10 ps equilibration stage at 
300 K and a production stage 1 ns molecular dynamics at 300 K in the NPT ensemble. Final 
peptide conformations from molecular dynamics were used as input receptor structures for a 
docking procedure. We used the CDocker protocol (BIOVIA) to generate a complex of each 
peptide with Aflatoxin molecule in order to calculate the binding energies between the two 
species and obtain the most interactive peptides against the Aflatoxin. For the best Aflatoxin 
M1 binding peptide discovered at the end of all screening steps, we calculated  the  binding 
energy of the complex with the “Calculate Binding Energies protocol” that estimates the 
binding energy between a receptor and a ligand. The binding energy was calculated using the 
following equation: EnergyBinding = EnergyComplex - EnergyLigand – EnergyReceptor 
[22]. 
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3.2.4 Surface plasmonic resonance 
The interactions between all 64 di-peptides and tetra-peptides were measured using the SPR 
technique with SensiQ Pioneer from AlfaTest  (Rome, Italy). In order to measure the affinity 
of the peptides (analyte) against the aflatoxin (ligand), AflatoxinM1-conjugated BSA  was 
immobilized at a concentration of 50 µg/mL in a 10 mM acetate buffer pH 3.7 (flow 10 
µL/min, injection time 20 min) on a COOH1 SensiQ sensor chip, using EDC/NHS chemistry 
(0.4 M EDC - 0.1 M NHS, flow 25µl/min, injection time 4 min), achieving a 7000 RU signal. 
Groups reactive residues were deactivated by treatment with ethanolamine hydrochloride 1 
M, pH 8.5. In order to study the aspecific binding of peptides against BSA, the reference 
channel was prepared by activation with EDC/NHS and immobilized with the BSA protein 
alone at a concentration of 50ug/mL and reaching the same RU signal of the toxin-BSA 
(7000). The binding assays were performed at 25 μL/min, with a contact time of 4 min, all 
peptides were diluted in the buffer stroke, HBS (10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 
pH 7.4).The injection of analytes (100 μL) was performed at the indicated concentrations. 
The association phase (kon) was followed for 180 s, whereas the dissociation phase (koff) was 
followed for 300 s. The complete dissociation of formed active complex was achieved by 
addition of 10 mM NaOH, for 60 s before each new cycle start. To subtract the signal of the 
reference channel and evaluate the kinetic and thermodynamic parameters of the complex, 
the software QDAT analysis package (SensiQ Pioneer, AlfaTest) was used. For tetra-peptide 
library binding experiments were conducted by Fast step injection. Fast Step is an in situ-
dilution method that enables stepped analyte gradient injections to be performed, where the 
concentration of sample steps up, or down, according to a predefined profile without reliance 
on dispersive mixing in a flow channel. The analyte concentration is modulated en route to 
the flow cell on-the-fly. This eliminates the overhead associated with multiple loading, 
injecting and clean up cycles making substantial reductions in time and complexity possible. 
The dissociation of analyte can be accurately estimated from a single dissociation phase 
curve recorded after the step injection is complete. The sample throughput can be increased 
by >10-fold compared to conventional methods. In this case an analyte concentration of 1mM 
was used with a flow rate of 200µL/min , a contact time of 20 sec and a dissociate time of 
120 sec. As to bulk standard cycles, a 20% of sucrose was used. Kinetic parameters for all 
tetra- peptides were estimated assuming a 1:1 binding model and using QDAT software 
(SensiQ Technologies). 
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3.2.5 Microfluidic device 
Microfluidic device consists of two inlets for the continuous and disperse phase, a narrow 
orifice in which the main channel and the two opposite channels converge, and a serpentine 
in which droplets were polymerized. The dimensions of the device are 50 × 35 µm (width × 
depth) for the channels solutions, 35 × 35 µm at the junction (width × depth); the serpentine 
is 10 cm long. The microfluidic device was fabricated by combining the conventional 
photolithographic and soft-lithographic techniques. Briefly, negative photoresist (Mr-DWL 
40 phtoresist, Microresist technology) was spun onto a silicon wafer at 2000 rpm for 30 s to 
make a 35 µm thick layer of photoresist. Then, the photoresist was baked and subsequently 
exposed using DWL 66 Fs LASER technology system (Heidelberg instruments). After the 
exposed sample had been post-baked and developed, the microfluidic flow focusing device 
master was prepared. The surface of the device mold was treated with tridecaﬂuoro-1,1,2,2-
tetrahydrooctyl-1-trichlorosilane to facilitate the peeling off of the polydimethyl-siloxane 
(PDMS, Sylgard 184, Dow Corning) replica. PDMS (10:1 polymer to curing agent) was 
poured on the patterned silicon wafer containing negative-channels. The PDMS-based 
microfluidic device was peeled off from the wafer and bonded on a glass slide with oxygen 
plasma treatment.  
3.2.6 Synthesis of Hybrid Peptide-Microgels . 
Microgels were synthesized using light mineral oil containing nonionic surfactant Span 80 (5 
wt%) as a continuous phase and poly(ethylene glycol)diacrylate (PEGDA) (20 wt%) with 
photoinitiator (0.1 wt%) and the three best Aflatoxin binding peptides (WNDNRD-(O-allyl)), 
WNDDRD-(O-allyl)), WNDPRD-(O-allyl)) at 80µM as disperse phase. Droplet emulsions 
were formed injecting prepolymer solution, the disperse phase, through the central channel 
whereas an oil solution, the continuous phase, through two opposite side channels. The 
uniform PEGDA-peptide droplets were crosslinked in flow to form monodisperse microgels. 
To photopolymerize droplets DAPI microscopy filter (9.8 mW, λ=360 nm) was used, 
focusing the UV light on the serpentine and regulating the diaphragm aperture of the 
microscope, for 15 s. After photopolymerization, microgels were collected in an eppendorf 
and washed three times with a solution of ethanol (35 v/v%) and acetone (10 v/v%) to 
remove the oil. After washing, microgels containing selected rhodamine-derivatized peptides 
were analyzed by confocal microscopy. Polyethylene tubes were connected to the inlets and 
outlets and the solutions were injected using high-precision syringe pumps (neMesys-low 
pressure) to ensure a reproducible, stable flow. This system was mounted on an inverted 
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microscope (IX 71 Olympus) and the droplets formation was visualized using a 4× objective 
and recorded with a CCD camera Imperx IGV-B0620M.  
Peptides were dissolved into the disperse phase and thanks to the allyl group at the C-
terminus of the sequences  they could co-polymerize with the PEG for the microgels 
synthesis. Fluorescent rhodaminated peptides were used to control the efficient microgels 
synthesis. Fluorescence analysis was performed by Leica SP5 confocal microscope. Bright 
field and fluorescence images using a HCX IRAPO L 40×/0.95 water objective were 
acquired; 540 nm line of the Argon laser as excitation sources for Rhodamine-peptide was 
used and detection occurred at the 600-700 nm band. Images were acquired with a resolution 
of 1024 × 1024 pixels, zoom 1, 2.33A.U. and maximum of pinhole (Figure 3.5). All our 
experiments were performed at room temperature.  
 
                                  
 
Figure 3.5: Confocal microscope images of Rhodamine-peptide microgels. A and B) Bright 
field and fluorescence images using a HCX IRAPO L 40×/0.95 water objective were 
acquired; 540 nm line of the Argon laser as excitation sources for Rhodamine-peptide was 
used and detection occurred at the 600-700nm band. C) Overlay of Bright field and 
fluorescent channels. 
 
3.2.7 Microgels Recovery by washing steps and SEM (Scanning electron miscroscopy) 
characterization 
Oil-dispersed microgels were recovered by an optimized washing protocol. Briefly, 1 mL of  
a mixed acetone/isopropanol/water solution (30:10:60) was added to the biphasic-system 
followed by centrifugation at 10000 rpm for 5 minutes, two times [16]. In this way the 
supernatant containing oil was eliminated and microgels were re-suspended in PBS buffer pH 
7.4 and stored at 4°C.   
In order to evaluate the correct oil elimination, SEM characterization with EDS analysis 
(Energy Dispersive X-ray Spectroscopy) was performed. SEM analysis was performed with a 
A B C 
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Ultra Plus FESEM scanning electron microscope (Zeiss, Germany). 10 µL of peptide 
microgels and PEG-microgels (without peptides, control negative microgels) solution of 
0.1mg/mL were mounted on microscope stubs, dried overnight  and sputter coated with gold 
(approximately 7 nm thickness). The same conditions were used for microgels before and 
after washing protocol. 
3.2.8 Fluorescamine assay 
Thanks to  the α amino group of the Aflatoxin binding peptides,  we evaluated the efficient 
and homogeneous peptide co-polymerization into microgels by a fluorescamine-based assay 
[17]. Fluorescamine was dissolved  in HPLC grade acetone (3 mg/mL) to obtain a 1 mM 
solution.. After 250 µΜ solution of fluorescamine was added to prepared samples and mixed 
for 15 minutes. Sample was loaded in ibidi channels and fluorescence analysis was performed 
by multiphoton confocal laser scanning microscopy (Leica SP5) using a two photon laser at 
700nm. Objective: HCX IRAPO L 40.0x0.95 WATER section thickness 3 µm, scan speed 
400 Hz, excitation MP laser 700nm, λem range 500–540nm, image size 1024 × 1024 µm
2
, 
zoom 1, 2.33A.U. and 600µm pinhole. All experiments were conducted at room temperature. 
The fluorescamine assay was perfomed both for peptide microgels and control negative 
microgels. All captured images were analysed with a public domain image-processing 
program, IMAGEJ (v. 1,43i, NIH, Bethesda, MD, USA). The images were briefly thresholded 
by the Otsu algorithm and then processed with the ImageJ Analyze Particles function to 
computationally determine the number of single fluorescent particles in the range of 20 µm. 
3.2.9 Aflatoxin binding and characterization in buffer and milk samples 
Binding experiments were performed incubating Aflatoxin binding peptide-microgels and 
microgels without peptide (Control-microgels) with Aflatoxin M1-BSA conjugated in PBS 
(pH 7.4) at room temperature for 2 h. To demonstrate the ability of our system to detect 
aflatoxin, 5µL of Aflatoxin binding peptide-microgels were suspended in 100µL of PBS and 
different concentrations of AFM1-BSA ranging from 0.0025nM to 2nM were added and 
incubated for 2 h. After the incubation, microgels were directly loaded in ibidi channels 
without any washing in order to not affect binding equilibrium between microgels and 
AFM1-BSA molecules; and the auto-fluorescence of AFM1-BSA in microgels was analyzed. 
The same protocol was used for microgels without peptide, as a negative control. 
Fluorescence analysis was performed by multiphoton confocal laser scanning microscopy 
(Leica SP5) using a two photon laser at 700nm. Objective: HCX IRAPO L 40.0x0.95 
WATER section thickness 3 µm, scan speed 400 Hz, excitation MP laser 700nm, λem range 
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400-500nm, image size 1024 × 1024 µm
2
, zoom 1, 2.33A.U. and 600µm pinhole. All 
experiments were conducted at room temperature. The same experiments were performed 
both for peptide-microgels and control microgels dispersed into milk solutions. Skim milk 
was purchased from a local grocery store and spiked with the same AFM1-BSA solutions 
used in the protocol for buffer samples. Before binding experiments, the milk was diluted 
with water (1:10) in order to decrease milk-proteins concentrations and avoid aspecific 
signals. For milk samples experiments, even AFM1 toxin without BSA conjugation was used. 
All captured images were analysed with a public domain image-processing program, IMAGEJ 
(v. 1,43i, NIH, Bethesda, MD, USA). The images were briefly thresholded by the Otsu 
algorithm and then processed with the ImageJ Analyze Particles function to computationally 
determine the number of single fluorescent particles in the range of 20 µm. 
 
3.3 RESULTS AND DISCUSSIONS 
The aim of this work was to obtain a synthetic system that could mimic recognition 
properties of the antibodies and possibly substitute them into the affinity media. We exploited 
combinatorial chemistry to synthesize libraries from which we could select a compound with 
recognition properties towards Aflatoxin M1. We performed two different combinatorial 
approaches: Computational and Experimental. Peptides sequences selected by proposed 
approach was then easily co-polymerized into PEGDA microparticles opening the route 
towards a direct detection of aflatoxins in small volume both in liquid and solid 
environments. 
3.3.1 Experimental library design and synthesis 
The aim of this work was to obtain a synthetic system that could mimic recognition 
properties of the antibodies and possibly substitute them into the affinity media. We decided 
to exploit combinatorial chemistry to synthesize libraries from which we could select a 
compound with recognition properties towards Aflatoxin M1 with high affinity. We 
combined two different approaches: Computational and Experimental. Peptides sequences 
selected by proposed approach were then easily integrated in PEGDA microparticles opening 
the route towards a direct detection of aflatoxins in small volume both in liquid and solid 
environments. 
Because of their chemical properties (i.e. solubility, different functional groups), their high 
availability and their low cost, we decided to use amino-acids to construct our library [18]. 
The amino-acids chosen to prepare library were Alanine (A), Arginine (R),  Aspartic Acid 
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(D), Asparagine (N), Threonine (T), Proline (P), Isoleucine (I), Tryptophan (W), which have 
different functional groups in their side chains and different chemical properties; in particular 
we tried to choose one amino-acid for each chemical category and so we simplified the 
composition of the library by neglecting other amino-acids. In this way we could easily 
obtain a known linear peptide sequence using an 8x8 amino-acids matrix as reported in figure 
3.6. As a solid phase Rink amide resin (substitution 0.71 mmol/g) was used; this support was 
suitable for the synthesis work because of their large size (50–100 mesh) and their easiness to 
handle and separate. In this way 64 different linear di-peptides were obtained. After SPR 
screening (See Chapter 3.3.3 for details), di-peptide “ND” with the best binding properties 
towards the aflatoxin M1 was used as starting point for the synthesis of a new linear 
tetrapeptide library. The same amino-acids previously employed were added as building 
blocks. The Aflatoxin M1 binding tetra-peptides were subsequently screened by SPR 
technique (See Chapter 3.3.3.2 for details) in order to find a high affinity binder. 
 
                          
    
Figure 3.6: Design of parallel peptide simplified library (one amino-acid for each chemical 
property): 8x8 aminoacids library matrix : 8
2 
= 64 possible di-peptides for each step. The 
same scheme was used for the construction of the tetra-peptide library using as starting point 
(first and second amino-acid) the best Aflatoxin M1 binding peptides screened by SPR. 
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3.3.2 In silico screening – Cdocker results 
In silico is an expression used to mean "performed on computer or via computer simulation." 
It is a computational technique used in drug discovery to search libraries of small molecules 
in order to identify those structures which are most likely to bind to a drug target, typically a 
protein receptor or enzyme [19]. Given a set of structurally diverse ligands that bind to a 
receptor, a model of the receptor can be built by exploiting the collective information 
contained in such set of ligands. These are known as pharmacophore models. A candidate 
ligand can then be compared to the pharmacophore model to determine whether it is 
compatible with it and therefore likely to bind [20]. CDOCKER is a CHARMm-based 
docking algorithm. Using a CHARMm-based MD simulation scheme,CDOCKER docks 
ligands in a receptor binding site. In this method, random ligand conformations generated 
from a high-temperature MD are first translated into the binding site. The binding poses are 
searched using random rigid-body rotations, followed by simulated annealing with a grid 
potential. A final minimization with full forcefield potential is used to refine the ligand poses 
[21]. Molecular Docking experiments between Aflatoxin M1 and 64 different peptides were 
performed using Cdocker, an algorithm available within Discovery Studio software. In 
particular, all 64 structures obtained from the library (See Experimental Section for details of 
library construction) have been properly designed, parameterized and minimized. After this 
both the toxin and peptide sequences were balanced by molecular dynamic. For the 
assignment of the charges we have chosen CharMm method and the force-field used was the 
“Momany-Rone” available within the program. So the minimized sequences and toxin were 
analyzed by Cdocker algorithm in order to have a binding energy of the interaction. This 
screening was repeated twice in order to have tetrapeptides able to bind Aflatoxin M1. As to 
the second screening, in according to Cdocker data of the first one and the SPR data, the di-
peptide sequence “ND” was chosen as starting point for the construction of the tetra-peptide 
library. In Figure 3.7 the binding energies of the first and second screening were reported, 
while best sequences of first and second screening were reported in figure 3.8. The docking 
results of all sequences for first and second screening were reported in Appendix of chapter 3. 
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Figure 3.7: Cdocker results of first and second screening: A) Binding energy values of di-
B 
A 
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peptide library towards Aflatoxin M1. B) Binding energy values of tetra-peptide library 
towards Aflatoxin M1. 
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FIGURE 3.8: Best Aflatoxin M1 binding di-peptide sequences selected from first screening 
performed by Cdocker results. From top left to the bottom the di-peptide sequences are: 
AD,AN,AR,DD,DN,DR,II,IN,IW,NI,NN,NW,PI,PW,PA,RW,RT,RD,TW,TR,TT,WW,WR,
WN. 
 
FIGURE 3.9: Best Aflatoxin M1 binding tetra-peptide sequences selected from second 
screening performed by Cdocker results.  
From top left to the bottom the tetra-peptide sequences are: 
NDAP,NDAW,NDDI,NDDP,NDID,NDIP,NDNR,NDNI,NDPR,NDPD,NDTP,NDTW,NDR
P,NDRW,NDWN,NDWT. 
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3.3.2.1 Calculation of binding energy of the complex between the best tetra-peptide 
sequences and Aflatoxin M1. 
In according to SPR screening (See paragraph 3.3.3 for details) and Cdocker results for the 
tetra-peptide library, three best Aflatoxin M1 binding peptides (WNDNR,WNDDR,WNDPR) 
were selected to calculate also the real Binding Energy value of the formed complex between 
peptides and toxin [22]. In addition, we also added a tryptophan residue (W) at the N-
terminal end of these three sequences in order to increase the affinity of them towards 
Aflatoxin M1. We decided to add this amino- acid as a sort of tag because of its aromatic 
properties that seem to be preferred by toxin both in Docking and SPR experiments. The tag 
addition increased the affinity between WNDPR peptide and toxin but it was negligible for 
WNDNR and WNDDR peptides. For this last two sequences, in-fact, it was not able to 
calculate the Binding Energy value of the total complex formed within the toxin. Despite of 
this we decided to use even this two peptides for material integration in according to good 
SPR obtained  results. In figure 3.10, the complex formed by toxin and WNDPR peptide was 
reported and the Binding Energy value was calculated to be -48.4442 kcal/mol. 
 
 
Figure 3.10: Binding Energy calculation of Aflatoxin M1/WNDPR complex. 
 
3.3.3 Surface plasmonic resonance (SPR) results  
All 64 synthesized peptides were analyzed by SPR experiments in order to evaluate their 
ability to bind aflatoxin. In SPR experiment Aflatoxin-M1-conjugated BSA was used as 
ligand and immobilized on the chip COOH1, achieving 7000 RU immobilization level 
according to reported conditions (see Experimental section for details).  
For the first screening, the direct binding between toxin-BSA and all 64 peptides were 
performed by injecting a fixed concentration of 3mM of all 64 peptides using a standard 
WNDPR Binding Energy= -48.4442 kcal/mol  
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protocol. As it is possible to see in figure 3.11, the highest RU signal was given by di-
peptides containing W (tryptophan) residues but they gave a high non specific signal on BSA 
reference channel as well (data not shown, we reported the RU values from channel one 
subtraction to channel 3). For this reason the Asparagine-Aspartic acid di-peptide (one letter 
code: ND) was chosen as starting point for the tetra-peptide library construction. This 
sequence, in-fact, gave a reasonable RU signal on toxin channel and no signal on BSA 
reference channel, highlighting the presence of a real specific binding between this di-peptide 
and Aflatoxin M1. For the “ND” peptide, a dose response experiment towards aflatoxin-BSA 
was also performed by injecting peptide solutions at increasing concentrations from 1.5µM to 
1mM. Employing a 1:1 interaction model, a high micromolar dissociation value for ND 
peptide/ Aflatoxin M1-BSA complex was shown. A good fitting was obtained using a 1:1 
interaction model. In figure 3.12 the dose-response overlay of ND sensorgrams and KD 
calculation was reported. All fitted sensorgrams for entire library were reported in Appendix 
of chapter 3. 
                          
 
Figure 3.11: RU values of all 64 di-peptides of first screening towards Aflatoxin-M1 channel. 
For each peptides a fixed concentration of 3mM was injected. The final RU signal was 
obtained by subtracting the BSA reference channel. 
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Figure 3.12: Binding of ND peptide and Aflatoxin M1 molecule. Conventional SPR 
experiment, analyte concentration from 1.5 µM to 1mM. 
In order to improve the affinity of selected ND peptide towards toxin, a tetra-peptide library 
was synthesized using ND sequence as starting point. So a SPR screening of this second 
library was performed. To avoid aspecific signals on reference channels (Channel 2 and 
BSA-channel 3), due to the entrapment of small peptides on polymer surface of sensor chip 
using conventional method, we decided to perform a Fast injection for the second screening. 
Fast Step is an in situ-dilution method that enables stepped analyte gradient injections to be 
performed where the concentration of sample steps up, or down, according to a predefined 
profile without reliance on dispersive mixing in a flow channel. The analyte concentration is 
modulated en route to the flow cell on-the-fly [23]. This eliminates the overhead associated 
with multiple loading, injecting and clean up cycles making substantial reductions in time and 
complexity possible (Figure 3.13). The dissociation of analyte can be accurately estimated 
from a single dissociation phase curve recorded after the step injection is complete. The 
sample throughput can be increased by >10-fold compared to conventional methods. 
 
Figure 3.13: Fast step methodology. 
     ND [  ] = From 1mM to 1.5µM  
KD = 1.5mM 
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So returning on our experiment, a fixed concentration of 500 M of all 64 tetra-peptides was 
injected and diluted directly into instrument flow-cell. Employing a 1:1 interaction model, a 
micromolar dissociation value (both with kinetic and equilibrium parameters) for six peptides 
(NDNR, NDRN, NDDR, NDRD, NDRP, NDPR) of the entire library was calculated as 
reported in figure 3.14a and b and in table 2, while for the other tetra-peptides there was no a 
clear association to the toxin showing typical aspecific sensorgrams with a low millimolar 
dissociation value, (See Appendix of chapter 3 for all fitted sensorgrams) 
 
 
 
   
 
 
 
 
 
 
 
 
A B C
D
E F
  a 
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b 
 
Figure 3.14: Fast step results of the best six tetra-peptides from the second screening. Fast 
step fitted sensorgrams using kinetic parameters (a) and equilibrium parameters (b). (a)From 
the top left the sequences reported are: NDRN, NDRD, NDRP, NDDR, NDNR, NDPR. The 
KD values are reported in table below. 
 
 
 
   Table 2: KD evaluation with kinetic and equilibrium parameters. 
 
In according to Docking experiments three of these sequences (NDNR,NDDR,NDPR)  were 
selected for material integration and for biosensors development. In particular even if the 
 78 
 
sequence NDPR had a high KD constant value, we decided to choose it on the basis of 
docking  results because it was the best Aflatoxin M1binding peptide selected from docking 
screening. 
To these three sequences, we decided as previously mentioned to add a W residue at the N-
terminal portion with the aim to improve more the affinity of the NDNR, NDDR and NDPR 
peptides towards Aflatoxin M1.  
As Docking results, the tag addition was very satisfying for NDPR sequence but was 
negligible for  NDNR and NDDR peptides. Even in this experiment a Fast step injection was 
performed using a fixed concentration of 500µM for all three peptides.  A low micro-molar 
dissociation value, employing a 1:1 interaction model was calculated as reported in figure 
3.15. All RU signal were subtracted to BSA reference channel. 
 
 
Figure 3.15: Fast step injection of the best three selected tetra-peptides with tag (W residue) 
addition. From the top left the sequence are: WNDDR, WNDNR,WNDPR. For all peptides a 
concentration of 500µM was used and a low micro-molar dissociation value, employing a 1:1 
interaction model was calculated. For WNDDR the KD was about 81±0.5µM, for WNDNR 
was 138±0.02 µM and for WNDPR was about 233±0.05µM. 
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So at the end of all library screening we decided to use the sequences: WNDNR, 
WNDDR,WNDPR to development and synthesized the final biosensor. 
3.3.4 PEGDA-peptide microgels synthesis and characterization 
Here microfluidic synthesis of biodegradable PEGDA-peptide microgels for Aflatoxin M1 
detection was reported. To functionalize the microgels we used three different tetra-peptides 
sequences selected from Docking experiments and SPR technology. In order to co-
polymerize these sequences with PEG into microgels, an allyl group at the C-terminal end of 
each peptide was added. Microgels synthesis and peptide attachment was described in 
Experimental Section. Briefly, the pre-polymer solution containing selected peptides 
(WNDNRD(allyl), or WNDDRD(allyl), or WNDPRD(allyl)) was injected through the central 
channel of the microfluidic device, as disperse phase, and an oil solution with surfactant was 
flushed through its two opposite side channels, as continuous phase. Under optimized flow 
rate conditions, estimated by CFD simulation, disperse phase was sheared into monodisperse 
droplets by continuous phase. Based on flow conditions, the yield of microgel production was 
around 300 microgel/minutes and the number of microgels was about 2x10
6
 particles/mL. 
This number was calculated using a cell counting chamber (data not shown). Alfatoxin M1 
binding peptide-microgels obtained are monodisperse in size and peptide encapsulation was 
confirmed by confocal image (Figure 3.5 in Experimental section). PEGDA has been chosen 
for its advantages over other polymers and its specific proprieties, such as good 
biocompatibility, non-toxicity, low immunogenicity in vivo, and resistance to protein 
adsorption. Moreover, polyethylene glycol (PEG) hydrogels are widely used in biomedical 
fields such as drug delivery and tissue engineering [24, 25]. 
3.3.5 Microgels Recovery by washing steps and SEM (Scanning electron miscroscopy) 
characterization 
In order to evaluate the correct oil elimination, SEM characterization with EDS analysis 
(Energy Dispersive X-ray Spectroscopy) was performed. For recovery protocol a solution of 
acetone/isopropanol/water (30/10/60) was used. This mixture caused a significant change in 
particle shape and surface morphology, as shown in Figure 3.16 A and B, where microgels 
washed and not washed were represented. In particular washed microgels had a good 
sphericity and a rough surface. The roughness was once more due to use of dehydrating 
solvents. Water extraction appears to change the PEGDA microgels network. Unlike, not 
good sphericity and smooth surface was detected on not washed microgels structure. The 
smooth and dense microgels surface were due to residual surfactants and oil (data confirmed 
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also by UV spectra, not shown here), as it is possible to see in EDS experiments (figure 3.17) 
[16].  All these considerations were validated both for peptide-microgels and control-negative 
microgels. 
 
 
              
 
 
             
A
--
- 
                       WASHED MICROGELS 
                 NO WASHED MICROGELS 
B 
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Figure 3.16: SEM images of peptide and control negative microgels. A) Washed microgels: 
From the top left the WNDPR, WNDNR, WNDDR and PEG microgels were represented. 
They showed a good sphericity and a rough surface. The roughness was once more due to use 
of dehydrating solvents. B) No washed microgels: From the top left the WNDPR, WNDNR, 
WNDDR and PEG microgels were represented; They had not good sphericity and smooth 
surface. The smooth and dense microgels surface were due to residual surfactants and oil. 
 
 
Figure 3.17: Example of EDS images for control negative microgels and WNDPR ones. On 
the top the no washed microgels were represented. In this image it is possible to see the 
presecence of oil and surfactants retained on microgels surface. On the bottom of the figure, 
the washed microgels were reported. In this case it is possible to see only the presence of 
cationic and anionic elements presented in buffer solution. 
 
3.3.6 Fluorescamine assay 
Thanks to the α amino group of the Aflatoxin binding peptides, we evaluated the efficient and 
homogeneous peptide co-polymerization into microgels by a fluorescamine-based assay. 
Fluorescamine is a common probe used to quantify protein or peptides in complex solutions. 
The non-fluorescent compound, fluorescamine, reacts rapidly with primary amines in 
PEG microgels no washed WNDPR microgels no washed
WNDNPR microgels washedPEG microgels washed
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proteins, such as the terminal amino group of peptides and the e-amino group of lysine, to 
form highly fluorescent moieties [26-28]. In our work, four different samples for each peptide 
microgels were treated with 250µM of fluorescamine solution for 15 minutes. The images 
were performed by multiphoton confocal laser scanning microscopy using a two photon laser 
at 700nm and the fluorescence analyzed by ImageJ tools (Figure 3.19), (See Experimental 
section for details). As we can see in the figure 3.18, the amount of peptides all over 
microgels structure was homogeneous. The same experiment was performed for control 
negative microgels. 
          
Figure 3.18: Fluorescamine assay. Multiphoton confocal laser scanning miroscopy images, 
excitation laser 700nm. The amount of peptide into microgels was homogeneous. For control 
negative microgels, the signal was very low similar to the laser background. 
WNDDR WNDPR
WNDNR PEG
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Figure 3.19: Fluorescence quantification by Image J tool. The amount of peptides into 
microgels was reproducible and homogeneous. The fluorescence signal of control negative 
microgels was very low, similar to no functionalized microgels. 
 
3.3.7 Aflatoxin M1-BSA conjugated binding and characterization in buffer samples 
The use of peptide-binding small molecules in polymeric networks is useful to have a 
selective platform for small molecules detection in complex mixtures. The binding between 
Aflatoxin M1-conjugated BSA and WNDNR,WNDDR,WNDPR peptides were determined 
suspending peptide-microgels in several buffer solutions containing different concentrations 
of toxin (see Experimental section for details). The selective binding of our system was 
demonstrated using the same protocol for control negative-microgels synthesized without 
peptide. All images were perfomed by multiphoton confocal scanning microscopy using 700 
nm as excitation laser. The quantification of Aflatoxin M1-BSA into microgels was 
performed by ImageJ tools, analyzing the fluorescence of the toxin into the single microgel. 
All three peptides were able to bind toxin, even if the best sequence is the peptide WNDPR in 
according with Docking results as well. In particular, in-fact, the WNDNR and WNDDR 
were not able to reach a saturation point in the range of concentrations used in this work, 
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while the WNDPR peptide reached a saturation just at concentration of 0.1nM, that was the 
legal accepted limit by Normativa 10 del 9-6-99; recepimento Reg.CEE 1528/98. So the 
integration of this new discovered peptide in a PEGDA microgel was very useful for the 
development of a biosensor for Aflatoxin contamination detection in foodstuff at very low 
concentrations. In figure 3.20 A, B, and C the fluorescence images of binding between 
aflatoxin and peptide-microgels were reported, also the control-negative microgel images 
were represented (Figure 3.20 D). In figure 3.21, the quantification of fluorescence intensity 
of WNDPR microgels after binding was reported. It was dose-responsive and specific with a 
KD about picomolar range. The fitting of other sequences was not reported because of their 
not saturation point reaching. For this reason and because of the accepted limit of Aflatoxin 
M1 in food are very low, we decided to select only WNDPR peptide for experiments in milk 
solutions.  
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Figure 3.20: Multiphoton confocal images of binding between Aflatoxin M1-BSA conjugated 
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and WNDNR (A), WNDDR (B), WNDPR (C) and control negative microgels (D). Excitation 
laser 700nm, emission 400-500nm. 
 
Figure 3.21: Quantification of fluorescent intensity of WNDPR microgels. A) Quantification 
of fluorescent of single microgels using ImageJ tools. B) Fitting of binding event between 
WNDPR peptide and Aflatoxin M1-conjugated BSA using a One-site specific binding as 
model with a non linear regression approach (C). 
 
3.3.8 Aflatoxin M1-BSA conjugated binding and characterization in milk samples 
Aflatoxin M1 (AFM1) in milk and milk products is considered to pose certain hygienic risks 
for human health.  Human beings that ingest aflatoxin B1 contaminated diets eliminate into 
milk amounts of the principal 4-hydroxylated metabolite known as “milk-toxin” or aflatoxin 
M1,(figure 3.1) [29]. International Agency for Research on Cancer (IARC, 1993) classified 
AFB1 and AFM1 as class 1 and 2B (or probable) human carcinogens, respectively, (milk 
review). It seems that milk has the greatest demonstrated potential for introducing aflatoxin 
residues from edible animal tissues into human diet. Moreover, as milk is the main nutrient 
for growing young, whose vulnerability is notable and potentially more sensitive than that of 
adults, the occurrence of AFM1 in human breast milk, commercially available milk, and milk 
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products is one of the most serious problems of food hygiene [29].  Because of the 
complexity of milk matrix, it is very difficult to process and destroy Aflatoxin M1 
contamination without losing milk properties. For this reason we develop a peptide-based 
biosensor that is able to recognize aflatoxin in a very sensitive way. 
On the basis of experiments of previous paragraphs, we decided to use only WNDPR as 
selected peptide to synthesize and develop our final biosensor. This peptide sequence, in-fact, 
showed the best binding properties towards Aflatoxin M1 when it was integrated in PEGDA 
microgels. These results were consistent with Docking experiments as well. Skim milk was 
purchased from a local grocery store and spiked with the same AFM1-BSA solutions used in 
the protocol for buffer samples (See Experimental section for details). Before binding 
experiments, the milk was diluted with water (1:10) in order to decrease milk-proteins 
concentrations and avoid aspecific signals. The selective binding of our system was 
demonstrated using the same protocol for control negative-microgels synthesized without 
peptide. All images were performed by multiphoton confocal scanning microscopy using 700 
nm as excitation laser and 400-500 nm as emission laser. The quantification of Aflatoxin M1 
autofluorescence into microgels was performed by ImageJ tools, analyzing the fluorescence 
of the single microgel. Even in this case, the peptide WNDPR showed a very good and 
specific recognition properties towards toxin also at very low aflatoxin concentrations 
respecting the legal accepted limit by Normativa 10 del 9-6-99; recepimento Reg.CEE 
1528/98. This confirm the ability of our peptide to detect aflatoxin also in milk sample in a 
very sensitive way. In figure 3.22 A the fluorescence images of binding between aflatoxin 
and WNDPR microgels were reported, also the control-negative microgel images were 
represented (Figure 3.22 B). In figure 3.23 A the quantification of fluorescence intensity of 
WNDPR microgels after binding was reported. It was dose-responsive and specific signal 
with a KD about low nanomolar range (B-C). For control negative microgels the fluorescence 
signal was very low respect to WNDPR microgels  and the fitting was not evaluable, (figure 
3.24 A,B,C,D). 
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Figure 3.22: Multiphoton confocal images of binding between Aflatoxin M1-BSA conjugated and (A) 
WNDPR peptide and (B) control negative microgels in milk sample. Excitation laser 700nm, emission 
400-500nm. 
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Figure 3.23: Quantification of fluorescent intensity of WNDPR microgels in milk sample. A) 
Quantification of fluorescent signal of single microgels using ImageJ tools. B) Fitting of 
binding event between WNDPR peptide and Aflatoxin M1-BSA conjugated using a One-site 
total binding as model with a non linear regression approach (C). 
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Figure 3.24: Quantification of fluorescent intensity of control negative microgels in milk 
sample. A) Quantification of fluorescent signal of single microgels using ImageJ tools. B) 
Fitting of binding event between control negative microgels and Aflatoxin M1-BSA 
conjugated using a One-site total binding as model with a non linear regression approach, KD 
not evaluable. C) Comparison of fitting of WNDPR microgels and control negative microgels 
using a One-site total binding as model with a non linear regression approach. 
 
In order to improve sensibility of our biosensor, we decided to change microgels numbers in 
binding experiments. A dilution of 1:10 about microgel solution was used to perform new 
binding experiments, in this case the number of microgels in contact with aflatoxin was about 
80. Using a lower number of microgels, we were able to improve biosensor sensibility in 
aflatoxin recognition at very low concentrations (Figure 3.25). On the basis of these new 
results, we can confirm that our system could be a promising discovery in aflatoxin detection 
in milk samples.  
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3.3.8.1 Aflatoxin M1 binding and characterization in milk samples 
With the aim to confirm the real specificity and  sensibility of our biosensor, a binding assay 
between WNDPR microgels and the only Aflatoxin M1 without BSA conjugation was 
performed. For this experiment four different concentrations of aflatoxin were used: 0, 0.01, 
0.1, 2 nM. All images were performed by multiphoton confocal scanning microscopy using 
700 nm as excitation  laser and  400-500 nm  as emission  laser. The quantification of 
Aflatoxin M1 auto-fluorescence into microgels was performed by ImageJ tools, analyzing the 
fluorescence of the single microgel. As it is possible to see in figure 3.26 A and B,C,D, the 
biosensor developed in this work was able to recognize aflatoxin contamination in milk 
sample in a very specific manner, opening an important way in aflatoxin food contamination 
in the agricultural and industrial fields. 
 
Figure 3.25: Binding between Aflatoxin M1-BSA conjugated and WNDPR microgels using a number 
of microgels diluted 1:10. A) Multiphoton confocal images of binding between Aflatoxin M1-BSA 
conjugated and WNDPR peptide microgels in milk sample. Excitation laser 700nm, emission 400-
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500nm. B) Comparison of fluorescence signal between WNDPR microgels and WNDPR one diluted 
1:10 after toxin binding. Using a lower number of microgels, there was an improvement on biosensor 
sensibility.  
 
 
Figure 3.26: Binding assay between WNDPR microgels and Aflatoxin M1 no BSA 
conjugated in milk sample. A) Multiphoton confocal images of binding between Aflatoxin 
M1 and WNDPR peptide microgels in milk sample. Excitation laser 700nm, emission 400-
500nm. B) Quantification of fluorescent signal of single microgels using ImageJ tools. C) 
Fitting of binding event between WNDPR peptide and Aflatoxin M1 using a One-site total 
and no specific binding as model with a non linear regression approach (D). The KD 
evaluated was about low picomolar range. 
 
3.4 CONCLUSIONS 
Aflatoxins are a group of highly toxic secondary metabolites produced by Aspergillus flavus 
and Aspergillus parasiticus. They are strong hepatotoxins and are internationally recognized 
as carcinogens [18]. Because of their strong chemical and thermal stability it is very difficult 
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to eliminate them from contaminated food. For this reason, over the last few decades, several 
methods for the identification and quantification of the aflatoxins have been developed [13]; 
however all of them present high costs and skilled quality control operators. So our work was 
based on the development of  a peptide-based biosensor for autofluorescence aflatoxin M1 
detection in milk samples, in a sensitive, specific and unsophisticated manner. With our 
synthetic and computational combinatorial approach we discovered a new synthetic peptide 
WNDPR that was able to recognize Aflatoxin M1. The affinity power of this peptide 
sequence was after improved, integrating it in PEGDA microgels and developing a real 
sensitive and specific biosensor for Aflatoxin detection in milk samples. The use of our 
biosensor could be open the rout towards a direct detection of aflatoxins in small volume both 
in liquid and solid environments. Our approach could be also applicable to other small 
molecules or contaminants whose sensitive detection is indispensable for food, biochemical 
or medical applications. 
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                                                                          Chapter 4 
 
Miniaturized microfluidic peptide-based device for 
biomedical and diagnostic applications; a specific case: 
Endometriosis disease 
ABSTRACT. There is always a great interest in the fabrication of protein-detecting arrays 
using immobilized capture agents in biomedical and diagnostic field [1]. While most efforts 
in this area have focused on the use of biomolecules such as antibodies and nucleic acid 
aptamers as capture agents, synthetic peptides might present many potential advantages. 
However, synthetic molecules isolated from combinatorial libraries generally are able to bind 
target proteins with the high affinity necessary for array applications. In this work three 
different peptides (CRP-1, VEGF-114 and ΦG6) were used as capture agents to detect serum 
levels of vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-a), 
and C-reactive protein (CRP): three serum markers of endometriosis in menstrual blood [2]. 
The selected peptides have been covalently immobilized on a microfluidic PDMS device, 
previously derivatized with 10% of PAA (Poly(acrylic acid)) solution. The so built device has 
been used to capture and recognize endometriosis markers both in buffer and biologic fluids 
matrices such as human serum with a good specificity and sensitivity. Our idea is to make up 
a miniaturized microdevice that is able to diagnose endometriosis from the earliest stages 
using peptides as capture agents in order to have a sensitive but not invasive and not 
expansive biosensor tool. 
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4.1 INTRODUCTION 
There is great interest in the development of micro-arrays that are able to monitor the levels 
and activities of a large numbers of proteins simultaneously [1]. One approach is to construct 
protein-detecting arrays using DNA, antibody and/ or aptamers as capture agents that 
recognize target protein with high affinity and specificity [3, 4]. The use of these 
macromolecules  are very expensive and for this reason the biosensor applications in medical 
fields are still very low. A significant challenge in the development of such technology could 
be the isolation of large numbers of suitable protein binding compounds [1]. Synthetic 
molecules can be produced in large quantities with efficient quality control and can be 
tailored to allow attachment to surfaces in a defined manner [1]. Also, macromolecules can 
easily lose their folded structure and so their activity at surface-solution interfaces, whereas 
this is not an evident issue with synthetic molecules. However, synthetic molecules isolated 
from combinatorial libraries generally can be able to bind target proteins with the high 
affinity necessary for array applications. Finally, some types of protein binding synthetic 
molecules like peptides can be economically produced and purified in large quantities than 
antibodies or aptamers. In this work three different peptides, were selected as ligand of three 
different biomarkers in menstrual blood related to endometriosis insurgence: tumor necrosis 
factor-α (TNF-α), vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) 
respectively. These sequences screened by SPR, phage display and FACS methodology 
respectively, showed high affinity for studied biomarkers [5-11]. Their affinity was 
confirmed by SPR-One step injection in this work. The selected peptides was covalently 
immobilized on a microfluidic PDMS device, previously derivatized with 10% of PAA (Poly 
(acrylic acid)) solution. The so built device was used to capture and recognize endometriosis 
markers both in buffer and biologic fluids matrices such as human serum with a good 
specificity and sensitivity. Endometriosis is an often painful disorder in which tissue that 
normally lines inside of uterus, the endometrium, grows outside uterus (endometrial implant) 
[12, 13]. The generation of new capillary blood vessels is probably required for the implant to 
grow larger than 2–3 mm, favoring an angiogenesis-dependent mechanism in endometriosis 
disease [12, 13]. Tumor necrosis factor-alpha (α) and vascular endothelial growth factor 
(VEGF) are important angiogenic factors. TNF-α is secreted by macrophages and it is a 
potent inducer of new blood vessel growth that produces proliferation of endometriotic 
stromal cells [14]. VEGF is a heparin binding growth factor with potent mitogen, morphogen 
and chemoattractant properties for endothelial cells. It increased in endometrium of 
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endometriosis patients, reflecting a critical pathogenic role. Serum C-reactive protein (CRP) 
is widely used as a marker of ongoing inflammation in several clinical diseases. CRP seems 
to be increased in women with endometriosis, especially in those with more advanced disease 
[15]. Although the use of serum biomarkers was still controversial, because of their low 
specificity in endometriosis disease and the low sensitivity of detection techniques 
performed, a non-surgical diagnostic approach could be of great benefit to both physicians 
and women alike [16].  In recent years, many efforts were made up to try to identify an easy 
way to diagnose endometriosis. The direct visualization of lesions at surgery preferably 
coupled with histologic confirmation of endometrial glands and stroma is the gold standard 
detection for endometriosis diagnosis. A surgical diagnosis has multiple drawbacks such as 
the risks inherent to the procedure (organ damage, hemorrhage, infection, and adhesion 
formation), as well as general anesthetic complications. Also patients need to travel to a 
hospital or outpatient surgicenter, with associated financial costs to the patient and the 
healthcare system [17].  For all these reasons, to develop a non-surgical diagnostic approach 
is very important in order to detect this disease from early stages. So the aim of this project 
was to make up a miniaturized microdevice that was able to diagnose endometriosis from the 
earliest stages using specific peptides as capture agents for these three VEGF, TNF-α and 
CRP biomarkers in order to have a sensitive but not invasive and not expansive biosensor 
tool for their determination and quantification. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials    
Reagents for peptide synthesis (Fmoc-protected amino acids, resins, activation, and 
deprotection reagents) were purchased from Iris Biotech GmbH (Waldershofer Str. 49-51 
95615 Marktredwitz, Deutschland) and InBios (Naples, Italy). 1-ethyl-3-(3-
dimethylaminopropyl)car-bodiimide hydrochloride(EDC), N-hydroxysuccinimide 
(NHS),PDMS and CRP (C-Reactive Protein)protein were fromSigma-Aldrich. VEGF 
(Recombinant Human VEGF165) was purchased from Peprotech.  Anti-CRP (Anti-C Reactive 
Protein antibody (FITC) (ab19174)) and Anti-VEGF (Anti-Recombinant Human VEGF 
antibody (FITC)) were from Abcam. TNF-α and Anti-TNF-α (Anti-Tumor Necrosis Factor-α 
antibody (FITC)) were from Prospec. Solvents for peptide synthesis and HPLC analyses were 
purchased from Sigma-Aldrich; reversed phase columns for peptide analysis and the LC–MS 
system were supplied respectively from Agilent Technologies and Waters (Milan, Italy). All 
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SPR reagents and chips were purchased from AlfaTest (Rome, Italy). PMMA substrates used 
in this study were purchased from the same batch of the polymer supplier (GoodFellow 
Cambridge Limited, England), Fluorolink S10 was from Solvay. Pooled human serum from 
healthy donors was supplied by Lonza (Life Technology Ltd, Paisley, UK). All chemicals 
were used as received. 
4.2.2 Peptide Synthesis 
Solid phase peptide synthesis of CRP-1, VEGF-114, G6 peptides and a model peptide was 
performed on a fully automated multichannel peptide synthesizer Biotage® Syro Wave™. 
The peptides were synthesized in the amidate version, employing the solid phase method on a 
50 μmol scale following standard Fmoc strategies. Rink-amide resin (substitution 0.7 
mmol/g) was used as solid support. Activation of amino acids was achieved using 
HBTU/HOBt/DIPEA (1:1:2). All couplings and deprotections were performed for 15 and 10 
min, respectively. Peptides were then removed from the resin, by treatment with a 
TFA/TIS/H2O (95:2.5:2.5, v/v/v) mixture for 90 min at room temperature; then, crude 
peptides were precipitated in cold ether, dissolved in a water/acetonitrile (1:1, v/v) mixture, 
and lyophilized. Products were purified by preparative RP-HPLC on a Waters 2535 
Quaternary Gradient Module, equipped with a 2489 UV/Visible detector and with an X-
Bridge
TM
 BEH300 preparative 10 × 100 mm C8, 5μm column, applying a linear gradient of 
0.1% TFA CH3CN in 0.1% TFA water from 5% to 70% over 30 min at a flow rate of  5 
mL/min. Peptides purity (97%) and identity was confirmed by LC–MS analyses carried out 
on an Agilent 6530 Accurate-Mass Q-TOF LC/MS spectrometer with Zorbax RRHD Eclipse 
Plus C18 2.1 x 50 mm, 1.8 µm columns. CRP-1 and VEGF-114 peptides were cyclized to 
obtain their active version. The cyclization process was performed using a concentration of 
0.1 mg/mL of peptides dissolved in 10mM phosphate buffer pH 7.4 for two days. The 
occurred reaction was confirmed by LC–MS analyses (See Appendix Chapter 4). Products 
were purified by preparative RP-HPLC applying a linear gradient of 0.1% TFA CH3CN in 
0.1% TFA water from 5% to 95% over 5 min at a flow rate of 5 mL/min. Purified peptide 
were lyophilized and stored at −20 °C until use. 
4.2.3 PDMS-PAA (Poly (acrylic acid)) derivatization  
All PDMS samples were submerged for 1’ in a 10% Benzophenone solution in ethanol and 
after they were treated with 15uL of different concentrations of PAA solution and covered 
with a rim glass [18-21]. They were irradiated with UV lamp at 360nm from 3 minutes to 1h. 
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The correct PAA- derivatization at different time of irradiation was monitoring by IR (Infra-
Red) spectroscopy, analyzing the presence of the acid band at 1717 cm
-1
. 
4.2.4 Peptide grafting on PDMS-PAA surface optimization by IR (Infra-red 
spectroscopy) and HPLC (High performance liquid chromatography) 
The peptide grafting was optimized with a model peptide: Ac-βA-G-R-A-A-Y-A-K-NH2. 
Different concentrations of peptide from 0 to 2mg/mL were used to grafted it on PDMS-PAA 
surface. In order to have a better and more stable complex we decided to link the peptide on 
our substrate with a covalent bond. The PAA surface was at first treated with 0.1M EDC/ 
0.2M NHS mixture in water for 10 minutes [22] and after peptide was grafted dissolving it in 
carbonate buffer 10 mM pH 8.5 at different concentrations. The formation of amide-bond 
was monitoring by IR analyzing the presence of peaks corresponding to amide I and amide II 
at 1660 and 1550 nm, respectively. In order to confirm the good amidation of PAA surface 
and to calculate the amount of adsorbed moles, peptide solutions were analyzed before and 
after PDMS-PAA grafting process by RP-HPLC, following tyrosine signal at 275nm.  
4.2.5 SPR (Surface Plasmonic Resonance) 
In order to evaluate and confirm the binding constant between peptide and biomarkers, SPR 
experiments were performed by One step injection. VEGF and CRP protein were 
immobilized at a concentration of 100 µg/mL in a 10 mM acetate buffer pH 4.5 and 3.5 
respectively, (flow 10 µL/min, injection time 20 min) on a COOH1 SensiQ sensor chip, using 
EDC/NHS chemistry (0.4 M EDC - 0.1 M NHS, flow 25µl/min, injection time 4 min), 
achieving a 800 RU signal. Groups reactive residues were deactivated by treatment with 
ethanolamine hydrochloride 1 M, pH 8.5. The reference channel was prepared by activation 
with EDC/NHS and deactivation with ethanolamine Analyte concentration of 30 µM for 
VEFG -114 peptide and 245 µM for CRP-1 peptide was used with a flow rate of 100 µL min-
1
 and a 300 sec of dissociation time.  In this kind of experiment, the volume of sample was 
configured as a percentage of the dispersion loop volume so in order to have a longer plateau 
at full concentration, the largest percentage (100%) was used. As to bulk standard cycles, a 
3% of sucrose was used. For all experiments Kinetic parameters for both peptides were 
estimated assuming a 1:1 binding model and using QDAT software (SensiQ Technologies). 
For G6 peptide, the affinity against TNFα was previously estimated by our research group in 
a recent study [9]. 
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4.2.6 Microfluidic device 
The depth and width of the three microchannel is equal, 300 µm width and 300 µm depth, 
and the chamber with an area of 67 mm
2
 is located at the end of the parallel microchannels. 
The pillars are 300 µm in diameter and 300 µm depth. The fabrication process consists of 4 
steps: (1) preparing the chip draft using Draftsight (Cad Software), (2) micromachining of 
PMMA layers; (3) the double PDMS replica (4) and finally the bonding process via oxygen-
plasma treatment. A micromilling machine (Minitech Machinery Corporation) was used to 
fabricate the PMMA master with the features of the final device. The certified positioning 
accuracy of the three-axis are 12”/300mm in x-axis, 9”/228mm in y-axis, and 9”/228 mm in 
z-axis. To standardize the fabrication process, the PMMA substrates used in this study were 
purchased from the same batch of the polymer supplier (GoodFellow Cambridge Limited, 
England). The microtools used in the microfabrication process were two flute endmills 300 
and 889 µm in diameter (Performace microtool, USA). During micromilling, spindle speed, 
feed speed and plunge rate per pass were set to 12.000 rpm, 15 mm s-1, and 20, respectively. 
After preparation of a PMMA master with negative features, open microchannels in PDMS 
were obtained by double replica molding onto the starting master. PDMS replica were 
fabricated from a mixture of PDMS precursor mixed in ratio 10:1 with curing agent and by 
using a thermal curing protocol at 80 °C for 2 h. Particularly, in order to prevent adhesion of 
the negative PDMS replicas on the positive PDMS mold, the latter was treated with oxygen 
plasma to activate the surface using a plasma chamber (Plasma prep II, SPI) for 1 min at a 
pressure of 0.3 mbar and power of 37 W and then immersed for about 2 min into a silane 
solution (i.e., a mixture of 94% v/v isopropanol,1% acetic acid, 1% Fluorolink S10 and 4% 
deionized water) and then placed in an oven at 75 °C for 1 h, thus allowing a complete 
reaction of the master surface with the fluorinated polymer [23]. To obtain the closed PDMS 
chip, we treated the final PDMS replica and a glass slide preciously coated with a thin PDMS 
layer through oxygen plasma activation , using a plasma chamber (Plasma prep II, SPI) for 1 
min at a pressure of 0.3 mbar and power of 37 W. The glass coating process involved 
depositing a small undiluted PDMS droplet (around 1 ml) onto the center of the glass and 
then spinning at high speed (2000 rpm for 20 s). Finally the bonding was then finalized in a 
controlled environment (temperature 80 °C for 2 h). 
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4.2.7 Selection of protein-binding peptides for specific marker detection and 
quantification 
Three peptides, V114; CRP-1; φG6, whose sequences are reported in Table 3 were derived 
from biopanning procedures[9-11], and synthesized by solide phase peptide synthesis. Table 
3 peptide sequences binnding endometriosis biomarkers VEGF, CRP, TNF-α. 
 
Peptide  Biomarker target Sequence 
φG6 TNF-α SSYYPQWPTDRF 
V114 VEGF VEPNCDIHVMWEWECFERL 
CRP-1 CRP EWACNDRGFNCQLQR 
 
The sequences were selected as ligand of three different biomarkers in menstrual blood 
related to endometriosis insurgence: tumor necrosis factor-α (TNF-α), vascular endothelial 
growth factor (VEGF), and C-reactive protein (CRP) respectively. 
Each peptide was immobilized on the PDMS-PAA surface in a microfluidic channels 
following the procedure above described (4.2.4) and filling the channel with a peptide 
solution at a concentration of 2 mg/mL.  Different concentrations of pure human recombinant 
TNF-α (Abcam) VEGF (Abcam), and CRP (Sigma Aldrich) proteins were solubilized in 
Phosphate-buffered saline (PBS) and incubated by flushing 25 µl of biomarker solutions into 
the corresponding channel for 2 hours. After incubation, the channels were washed 3 times 
with 3 ml of PBS.  
Biomarkers detection was performed by immunofluorescent detection through primary anti-
TNF-α, anti-VEGF, and anti-CRP antibody (Abcam), labeled with Alexa Fluor® 488, Alexa 
Fluor® 568, and Pacific Blue™ dye, respectively, by Molecular Probes® Antibody Labeling 
Kits (ThermoFisher Scientific). Fluorescence analysis was performed by Leica SP5 confocal 
microscope. Bright field and fluorescence images using a HCX IRAPO L 25×/0.95 water 
objective were acquired; Images were acquired with a resolution of 1024 × 1024 pixels, zoom 
1, 2.33A.U. All experiments were performed at room temperature. LOD range related to each 
was determined by image analysis through ImageJ tool [31] (https://imagej.nih.gov/ij/). 
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4.2.8 Setting of microfluidic device for endometriosis biomarkers 
Microfluidic device channels were functionalized for multiplex detection of endometriosis 
biomarkers. V114, CRP-1, and φG6 peptides were immobilized filling any channel with a 
PBS solution containing 2 mg/mL of one peptide as wall as previously described in 4.2.6.  the 
device was tested flushing 1 ml of a testing solution containing 5pmol of VEGF, CRP and 
TNF-α proteins in PBS. Functionalization through a scramble peptide (Ac-βA-G-R-A-A-Y-
A-K-NH2) was used for negative controls. The resident time of the testing solution was 2 
hours. After proteins incubation, the device was washed by 30ml of PBS and incubated with 
a mixed solution of primary fluorescent anti-VEGF, anti-CRP and anti-TNF-α antibody 
(dilution 1:10 in PBS) overnight.  Fluorescence analysis was performed by Leica SP5 
confocal microscope. Bright field and fluorescence images using a HCX IRAPO L 25×/0.95 
water objective were acquired; Images were acquired with a resolution of 1024 × 1024 pixels, 
zoom 1, 2.33A.U. Analogous experiments were performed detecting endometriosis 
biomarkers in human serum (1x), dissolved at 5 nM final concentration. Autoflorescence and 
background signal was determined by analysis of each channel surface incubated with PBS or 
human serum solution not containing biomarkers. All experiments were performed in 
triplicate at room temperature. For each sample 10 images of different zone of the surface 
was acquired under the microscope.  
 
4.3 RESULTS AND DISCUSSIONS 
In this work three different peptides (CRP-1, VEGF-114 and φG6), selected by literature, 
have been used as capture agents for human biomarkers: VEGF, TNF-α and CRP. The area of 
interest for these biomarkers spread in several diagnostic research fields. In particular, it has 
been postulated a future diagnostic tool for endometriosis will consist of a panel containing 
these proteins as biomarkers. As a fact, recent studies suggested that peritoneal fluid of 
endometriosis patients contains an increased number of activated macrophages that secrete 
local products with important angiogenic properties, including VEGF and TNF-α [24-26]. 
Moreover, serum C-reactive protein (CRP) is widely used as a marker of ongoing 
inflammation in clinical practice [2].  A health history and a physical examination can lead 
the health care practitioner to suspect endometriosis. Although doctors can often feel the 
endometrial growths during a pelvic exam, and these symptoms may be signs of 
endometriosis, diagnosis cannot be confirmed by exam only. Use of pelvic ultrasound may 
identify large endometriotic cysts (called endometriomas) [27]. However, smaller 
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endometriosis implants cannot be visualized with ultrasound technique. Our idea is to set up a 
miniaturized microdevice that is able to diagnose endometriosis from the earliest stages using 
peptides as capture agents in order to have a sensitive but not invasive and not expansive 
biosensor tool. Thus, the selected peptides were covalently immobilized on a microfluidic 
PDMS device, previously derivatized with 10% of PAA (Poly(acrylic acid)) solution, and 
tested for detection of VEGF, TNF-α and CRP in solution.  
4.3.1 PDMS-PAA (Poly (acrylic acid)) derivatization  
PAA brushes were grown on PDMS surface previously actived with a 10% Benzophenone 
solution in ethanol. The correct PAA-derivatization at different UV-irradiation time was 
monitoring by IR (Infra-Red) spectroscopy, analyzing the presence of the acid band at 1717 
cm
-1
. In figure 4.1, IR spectra of PDMS-PAA functionalization (10% of PAA-solution) at 
different UV-irradiation time periods, from 3 to 10 minutes were reported. The improvement 
of acid band at 1710 nm with the increasing time was very clear. From 7 to 10 minutes the 
saturation was reached.  
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Figure 4.1: IR spectra of PDMS-PAA functionalization at different time periods from 
3 to 10 minutes. It was clear the improvement of acid band at 1710 cm
-1 
with the 
increasing time. From 7 to 10 minutes the saturation was reached. 
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The figure 4.2 displayed the deconvolution of carbonyl stretching regions showed in figure 
4.1. The PAA-grafted surface increased during the time, reaching the saturation point of 
around 1.3-1.4 mg/cm
2 
between 10 and 15 minutes. 
    
    
 
 
 
 
 
  
 
Figure 4.2: Deconvolution of  carbonyl stretching region  at different time periods. The PAA 
grafted surface increased during the time, reaching the saturation point of around 1.3-
1.4mg/cm
2 
 between  10 and 15 minutes.   
4.3.2 Peptide grafting on PDMS-PAA surface optimization by IR (Infra-red 
spectroscopy) and HPLC (High performance liquid chromatography)  
The peptide grafting was optimized with a model peptide: Ac-βA-G-R-A-A-Y-A-K-NH2. 
Different concentrations of peptide from 0 to 2mg/mL were used to grafted it on PDMS-PAA 
surface. The PAA surface was at first treated with 0.1M EDC/ 0.2M NHS mixture in water 
for 10 minutes [22] and after with different concentrations of model peptide dissolved in 
carbonate buffer 10 mM pH 8.5. Figure 4.3 A showed the overlay of infrared spectra of 
PDMS-PAA surface before and after activation of PAA brushes with EDC/NHS mixture. The 
characteristic infrared bands classified as NHS-ester showed triplex bands at 1740, 1780, and 
1815 cm
-1
; while the degradation product of reaction, N-acylurea was associated to doublet 
bands of amide at 1550 and 1650 cm
-1
 (Figure 4.3 B). 
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Figure 4.3: A) IR spectra of PDMS-PAA surface before and after activation treatment with 
EDC/NHS (0.1M-0.2M). B) Zoom of the observed region before and after EDC/NHS 
treatment: NHS-ester three bands (1740-1780-1815cm
-1
), N-acylurea, degradation product of 
reaction, two bands (1550-1640cm
-1
). The dotted line showed the acid band (1710cm
-1
) 
before treatment that disappeared after activation. 
The main goal of EDC/NHS activation of carboxylic acids is to couple free amine-containing 
biomolecules [22]. Figure 4.4 showed the occurred amidation on PDMS-PAA surface after 
incubation with different solutions of model peptide (from 0.125 mg/mL to 2mg/mL), (figure 
4.4 A). The presence of two bands at 1550 and 1670 cm
-1
, corresponding to amide I (peptide 
C=O stretch) and amide II (mostly peptide N=H bend), stressed the proper peptide grafting 
on the surface (figure 4.4 C). Unlike, the presence of two amide bands on PDMS-PAA 
surface without pre-activation by EDC/NHS solution was very weak, (figure 4.4 B, D). In 
figure 4.5 (A,B) the quantification of the area of the amide and acid bands according to 
peptide concentrations, both for EDC/NHS treated surface and not was showed. The data 
were analyzed by software GraphPad Prism version 5.04. 
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Figure 4.4: IR spectra of PDMS-PAA after peptide amidation. A) Whole IR spectra of 
amidation reaction after EDC/NHS reaction at different concentrations of peptide from 
0.125mg/mL to 2mg/mL. B) IR spectra of amidation reaction without EDC/NHS treatment. 
C) and D) Zoom of observed area with activation treatment and without it respectively. In the 
first case the presence of the two amide bands (1550 and 1670 cm
-1
, amide I and II) was clear 
and they increase with improving peptide concentration. In the second one the presence of 
two amide bands was very weak. 
 
Amide I-II
1670-1550cm-1
Amide I-II
1670-1550cm-1
Without EDCWith EDC
A B
C D
      With EDC/NHS Without EDC/NHS 
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Figure 4.5: Quantification of the area of the amide and acid bands according to peptide 
concentrations. A) Sample treated with activation reaction. In this case the amide band was 
increased with peptide concentration, while acid band at 1710 cm
-1
 decreased. B) Sample 
without activation reaction. In this case only the acid band at 1717 cm
1 
was observed. 
In order to confirm the good amidation of PAA surface and to calculate the amount of 
adsorbed moles, peptide solutions were analyzed before and after PDMS-PAA grafting 
process by RP-HPLC, following tyrosine signal at 275nm. In the table 4 and 5 the amount of 
adsorbed moles were reported both for EDC/NHS treated surface and not treated PDMA-
PAA. The adsorbed moles were evaluated measuring peptide concentrations of unbound 
fraction after grafting process. A saturation point on treated surface was reached at 1 mg/mL 
of peptide concentration. A no linear response was obtained for not treated surface. The 
titration curve used for quantification was reported in the Appendix of chapter 4. In figure 4.6 
A the absorbance of bound fractions corresponding to different concentrations of peptide was 
reported for both surface. Also the amount of adsorbed moles/cm
2
 was reported, (Figure 4.6 
Model peptide
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B). For 2 mg/mL of peptide concentration, about 500 nanomoles/cm
2 
were linked on our 
device. 
Table 4: Quantification of adsorbed moles by RP-HPLC on PDMS-PAA surface previously 
activated by EDC/NHS 
 
Table 5: Quantification of adsorbed moles by RP-HPLC on PDMS-PAA surface not activated 
by EDC/NHS 
 
 
[ ] peptide mg/mL (surface 
with EDC/NHS treatment)
C bound mg/mL Moles adsorbed
0.25 0.18 53nmol
0.5 0.19 56nmol
1 0.43 126nmol
1.5 0.43 126nmol
2 0.43 126nmol
[ ] peptide mg/mL (surface 
without EDC/NHS treatment)
C bound mg/mL Moles adsorbed
0.25 0.036 10nmol
0.5 0.022 6.5nmol
1 0.09 26nmol
1.5 0.09 26nmol
2 0 0nmol
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Figure 4.6:  A) the absorbance of bound fractions corresponding to different concentrations of 
peptide was reported for both surface. B) the amount of adsorbed moles/cm
2
 was reported, 
For 2 mg/mL of peptide concentration, about 500 nanomoles/cm
2 
were linked on our device. 
4.3.3 SPR (Surface Plasmonic Resonance) 
In order to evaluate and confirm the binding constant between peptide and biomarkers SPR  
experiments were performed by One step injection. Analyte concentration of 30 µM for 
VEFG -114 peptide and 245 µM for CRP-1 peptide was used. One step experiment was based 
on Taylor dispersion theory, so a unique concentration of peptide was dispersed into running 
buffer directly in the flow cell in order to have a final sigmoidal profile [28-30] (Figure 4.7 
A,B). Employing a 1:1 interaction model, a low micromolar dissociation value for 
peptides/biomarkers was shown; it was in according to conventional SPR experiment 
reported in literature [10, 11]. For G6 peptide, the affinity against TNFα protein was 
previously estimated by our research group in a recent study (data not shown), [9]. 
A B 
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Figure 4.7: One Step injection experiments. A) Binding of CRP-1 (245µM) and CRP protein. 
The evaluated KD was 12±0.1 µM. B) Binding of VEGF-114 (30µM) and VEGF protein. 
The evaluated KD was 10 ±0.7 µM.  
4.3.4 Microfluidic device 
Microfluidic chip was obtained by coupling micromilling and soft lithography technology 
based on polydimethylsiloxane (PDMS). PDMS has been the most widely used material in 
the research and development of microfluidics for several reasons including its optical 
transparency. In addition, the fabrication of systems of microchannels in PDMS is 
particularly straightforward. They can be replicated on masters of different materials 
including poly methyl methacrylate (PMMA). Such material can be easily machined by a low 
cost and fast prototyping technique such as micromilling. Microfluidic chips can then be 
easily sealed by oxygen plasma treatment of the PDMS substrate. As shown in figure 4.8 by 
the CAD (Figure 4.8 A) and SEM image (Figure 4.8B) the microfluidic device is composed 
CRP-1
VEGF-114
A 
B 
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of three parallel channel converging in a chamber with micropillars which function is to 
support the large channel once bonded.  
 
Figure 4.8 CAD layout (A) and SEM image (B) of the microfluidic chip. 
4.3.5 Endometriosis biomarkers detection through peptide functionalized microfluidic 
device 
The affinity peptides V114; CRP-1; φG6, identified from phage display peptide libraries and 
FACS methodology [9-11], were employed here as biorecognition element for human VEGF, 
CRP and TNF-α biomarkers. 
The conjugation of each peptide to the channel surface was carried out allowing specific 
binding and detection of only one biomarker per channel. Thus, each channel was tested with 
different concentrations of the corresponding protein target in PBS and biomarker 
sequestration was revealed by immunofluorescent detection through primary fluorescent 
labeled antibodies. For each biomarker the LOD was determined by image analysis of the 
fluorescence detectable on the surface as reported in figure 4.9. 
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Figure 4.9: LOD determination and fluorescence analysis of studied biomarkers. 
The device is able to reveal the presence of biomarkers in solution at a nM order 
concentration, compatible with the physiological range of VEGF, CRP and TNF-α in 
menstrual blood of patient affected by endometriosis. In order to test suitability and 
specificity of the functionalized channels for multiplex analysis of endometriosis biomarkers, 
the microfluidic device was tested by flashing 1ml of PBS solution containing recombinant 
human VEGF, CRP and TNF-α proteins at 5nM final concentration. In this case the 
immunodetection was performed by incubating each microchannel of our device with a 
unique solution containing fluorescent anti-VEGF, anti-CRP and anti-TNF-α antibodies. The  
device was able to specifically detect the presence od each biomarker displaying the 
fluorescent signal only in the dedicated microchannel (figure 4.10)   
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Figure 4.10: Detection of endometriosis biomarkers dissolved in PBS solution flushed in 
functionalized microfluidic channel device. From left to the right the channels were 
functionalized with three different binding peptides as follow: V114; CRP-1; φG6 (figure 
4.10 A). immunofluorescence was performed with three different fluorescent antibodies: anti-
VEGF (figure 4.10 B), anti-CRP (figure 4.10 C), anti-TNF-α (figure 4.10 D). 
 
Finally, we conducted the same experiments in a complex biological modelby processing an 
human serum sample that contained the human EGF, CRP and TNF-α biomarkers at 5nM 
final concentration (figure 4.11). The fluorescence analysis display that the presence of 
human serum proteins does not affect the interaction of biomarkers with the corresponding 
binding peptides. Thus, the reported data confirmed the effective applicability of our system 
in the multiplex analysis for diagnostic purposes.  
 
 
Figure 4.11: Detection of endometriosis biomarkers dissolved in human serum solution 
flushed in functionalized microfluidic channel device. From left to the right the channels 
were functionalized with three different binding peptides as follow: V114; CRP-1; φG6 
(figure 4.11 A). Immunofluorescence was performed with three different fluorescent 
antibodies: anti-VEGF (figure 4.11 B), anti-CRP (figure 4.11 C), anti-TNF-α (figure 4.11 D). 
A merge of the fluorescent signals is reported in figure 4.11 E.  
 
A                                 B                                   C                                   D 
A                         B                            C                          D                         E 
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4.4 CONCLUSIONS 
There is great interest in the construction of protein-detecting microarrays agents in 
biomedical and diagnostic fields [1]. One approach is to construct protein-detecting arrays 
using macromolecules as capture agents [3,4]. The use of these macromolecules are very 
expansive and for this reason the biosensor applications in medical fields are still very low. A 
significant challenge in the development of such technology could be the isolation of large 
numbers of suitable protein binding compounds [1]. Synthetic molecules can be economically 
produced in large quantities with efficient quality control and can be tailored to allow 
attachment to surfaces in a defined manner. In this work three different peptides, selected by 
literature, was used as capture agents for three endometriosis protein markers: VEGF, TNF-α 
and CRP [5-8]. The selected peptides was covalently immobilized on a microfluidic PDMS 
device, previously derivatized with 10% of PAA (Poly (acrylic acid)) solution. The so built 
device was used to capture and recognize endometriosis markers both in buffer and biologic 
fluids matrices such as human serum with a good specificity and sensitivity. With our 
approach, we proposed a simply but efficient strategy to bind a peptide on a polymer surface 
in order to use it as capture protein agent. Our idea was to set up a miniaturized microdevice 
that was able to diagnose endometriosis from the earliest stages in order to have a sensitive 
but not invasive and not expansive biosensor tool. The obtained results could represent a new 
challenge in endometriosis diagnosis avoid all drawbacks (organ damage, hemorrhage, 
infection, and adhesion formation) connected to surgical diagnosis that today seems to be the 
gold standard method used in the diagnosis of endometriosis disease. 
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Di-peptide sequences of Cdocker results. 
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Tetra-peptide sequences of Cdocker results. 
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Di-peptide screening by SPR ( [ ] 3mM of each sequence) 
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Tetra-peptide screening by SPR ([ ] 1mM of each sequence), KD= high micromolar range. No good 
fitting for all sequences. 
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[M/2]+2
[M/3]+3
LC-MS of VEGF-114, ΦG6 and CRP-1 peptides.  
VEGF 114:VEPNCDIHVMWEWECFERL 
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[M/2]+2
[M-H]+
[M/2]+2[M/3]
+3
         ΦG6: SSYYPQWPTDRF 
CRP-1: EWACNDRGFNCQLQR 
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[M/2]+2
[M/3]+3
[M/2]+2
[M/3]+3
LC-MS of VEGF-114 and CRP-1 oxidized peptides.  
VEGF 114:VEPNCDIHVMWEWECFERL 
CRP-1: EWACNDRGFNCQLQR 
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